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Hope is the thing with feathers 
That perches in the soul, 
And sings the tune without the words. 
And never stops at all, 
And sweetest in the gale is heard; 
And sore must be the storm 
That could abash the little bird 
That kept so many warm. 
I've heard it in the chillest land, 
And on the strangest sea; 
Yet, never, in extremity, 
It asked a crumb of me. 
Emily Dickinson 
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Abstract 
FE65 (APBBl) is a brain-enriched adaptor protein which has been implicated in 
a variety of cellular functions including transcriptional regulation of genes, cell 
apoptosis, cell cycle regulation, cell migration and neuronal positioning. However, its 
precise cellular roles are still not clear. Importantly, it has been shown that FE65 
interacts with the Alzheimer's disease (AD) amyloid precursor protein via its 
phosphotyrosine-binding 2 (PTB2) domain. Although the mechanism is not known, a 
number of studies suggest that FE65 influences APP processing. In addition to the 
PTB2 domain, FE65 consists of two other protein binding domains, the PTBl and 
the WW domains. It is generally believed that proteins that bind these domains can 
contribute to the functions of FE65. In order to improve our understanding of the 
functions of FE65 and its role in AD pathogenesis, I have attempted to identify novel 
interacting partners of FE65. Here I have demonstrated that a small GTP-binding 
protein Arf6, which is important in endosomal recycling and actin remodeling, is 
able to interact directly with FE65 through its PTBl domain. 
In order to further characterize the interaction between Arf6 and FE65, a potent 
anti-Arf6 antibody would be essential. However, our laboratory has tested several 
commercially available anti-Arf6 antibodies and found that they could not detect 
endogenous Arf6. Thus I have generated anti-Arf6 antibodies by immunizing 
Sprague-Dawley rats with recombinant Arf6 protein. The polyclonal antibodies 
produced were effective in recognizing endogenous Arf6. In addition, by 
immunostaining analyses using these antibodies, it is observed that of FE65 and Arf6 
colocalize at perinuclear region in transfected cells. 
The findings of this project open novel avenues for investigating the functions 
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Chapter 1 Introduction 
1.1 FE65 
FE65 is a brain-enriched adaptor/scaffolding protein with continuously growing 
academic interest (Bressler et al., 1996; McLoughlin and Miller, 2008; Trommsdorff 
et al” 1998; Yang et al., 2006). It is involved in a vast number of cellular processes 
and is conserved among many different organisms (Duilio et al., 1991; McLoughlin 
and Miller, 2008; Russo et al., 1998). FE65 was firstly isolated through a cDNA 
library screen generated from 3-month-old rat brains in 1990 (Esposito et al., 1990). 
The name "FE65" refers to the initials of the first author (Franca Esposito) and the 
clone number of the cDNA clone (65). It aroused immediate interest since it is found 
to be developmentally regulated and it demonstrates high tissue specificity. The 
human FE65 gene is mapped on to chromosome l l p l 5 , and was subsequently 
assigned the gene name amyloid p (A4) precursor protein (APP)-binding, family B, 
member 1 (APBBl)(Blanco et al., 1998; Bressler et al., 1996). The naming of the 
gene is due to the significance of its strong interaction towards the C-terminal 
intracellular domain of APP (AICD), and the APP paralogues APP-like protein 1 
(APLPl) and APP-like protein 2 (APLP2) (Borg et al., 1996; Fiore et al., 1995; Lau 
et al., 2000; Muresan and Muresan, 2005). The binding of FE65 to the YENPTY 
motif of APP aroused much interest because it is the region related to the processing 
of APP, which is implicated in Alzheimer's disease, as the main component of senile 
plaques, Ap, is a cleavage product of APP (Borg et al., 1996; De Strooper et al., 1995; 
Perez et al., 1999). FE65 has subsequently been shown to influence the production of 
AP (Ando et al., 2001; Guenette et al., 1999; Sabo et al., 1999; Santiard-Baron et al., 
2005). In addition, it was proposed that FE65 could act as a DNA binding protein, 
since a region of the protein shows high homology to the DNA binding domain of 
retroviral integrases (Duilio et al., 1991). More recent findings provide strong 
support to this premise and show that FE65 is transcriptionally active (Cao and 
Sudhof, 2001; Kajiwara et al., 2009; Telese et al., 2005; Yang et al., 2006; Zambrano 
et al., 1998). 
The major full-length human FE65 protein is encoded by a 2.6 kb mRNA, 
which is spliced from a pre-mRNA consisting of 14 exons and encodes a protein 
consisting of 711 amino acid residues, which is around 97 kDa in size (Bressler et al., 
1996). It is the major isoform present in cells. However, other minor isoforms of 
FE65, either under post-transcriptional or post-translational modifications, are also 
reported (Hu et al., 1999). 
Subsequently two more paralogues of human FE65 were discovered, which 
were named amyloid p (A4) precursor protein-binding, family B, member 2 (APBB2, 
also known as FE65-like 1 or FE65L1) and amyloid (3 (A4) precursor protein-binding, 
family B, member 3 (APBB3, also known as FE65-like 2 or FE65L2) (Duilio et al., 
1998; Guenette et al., 1996). These FE65-like proteins were encoded from different 
genes. FE65L1 is mapped to chromosome 4pl4-pl3, while FE65L2 is mapped to 
chromosome 5q31 (Blanco et al., 1998; Tanahashi and Tabira, 1999a). 
1.1.1 FE65 Protein Family and Their Structures 
The three members of the human FE65 protein family, FE65, FE65L1 and 
FE65L2, are adaptor/scaffolding proteins that regulate the assembly of heteromeric 
protein complexes through protein interaction domains (Fiore et al., 1995; Guenette 
et a l , 1996; Tanahashi and Tabira, 2002). All FE65 proteins are structurally similar 
and contain three domains: an N-terminal WW domain and two contiguous 
phosphotyrosine binding domains, also known as phosphotyrosine interaction 
domains, (PTBl or PIDl; PTB2 or PID2), which are well-studied protein interaction 
domains (Bressler et al.，1996; Guenette et al., 1996; Sudol et al., 2001; Tanahashi 
and Tabira, 1999b; Uhlik et al., 2005). The differences in amino acid sequences of 
FE65, FE65L1 and FE65L2 mainly lay at the N-terminal region preceding the WW 
domains (Mc Loughlin and Miller, 2008). FE65 includes a 253-residue sequence 
before the WW domain, while FE65L1 and FE65L2 have a 290-residue and a 
29-residue preceding sequence, respectively. In addition, FE65L2 has a short 
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Fig 1 Schematic diagram showing domain structures of the human FE65 protein 
family. WW stands for the WW domains and PTB stands for the phosphotyrosine 
binding domains. The numberings code for the amino acid residues at the boundary 
of the protein domains. (Adopted from (McLoughlin and Miller, 2008)) 
1.1.1.1 WW domain 
The WW domain, which is found in a wide variety of signaling proteins, is a 
small protein module consisting of around 40 amino acids (Sudol et a l , 2001). The 
name ' W W refers to the presence of two signature tryptophan (W) residues that are 
spaced 20-22 amino acids apart and play a significant role in the structure and 
function of the domain (Sudol et a l , 2001). WW domains have strong affinity 
towards proline-rich peptides (Meiyappan et al., 2007). Proteins that lack a nuclear 
localization signal, including FE65, can be localized inside the nucleus through the 
interaction of the WW domain with other nuclear proteins (Sudol et al., 2001). Many 
WW domain-containing proteins can bind other partners and co-activate gene 
transcription, or directly regulate the activity of RNA Polymerase II on their own 
(Ingham et al., 2005; Sudol et al., 2001). 
The WW domain of FE65 belongs to Group II WW domains. It is a small 
module consisting of around 40 amino acid residues. It preferably binds ligands with 
the PPLP motif. It is reported that only by binding to other nuclear targeting or DNA 
binding proteins through its WW domain can FE65 function as a regulator of gene 
transcription. In addition, an intact WW domain is essential for the 
APP/FE65-regulated transcription (Cao and Sudhof, 2001). 
1.1.1.2 PTB domains 
The PTB domains, which specifically bind peptides with a NPXY motif, are 
present in many different proteins involved in neural development, immunity, tissue 
homeostasis and cell growth (Uhlik et a l , 2005). The name 'PTB，refers to the fact 
that the first discovered PTB-containing proteins bind their ligands in a 
phosphotyrosine-dependent manner (Margolis et a l , 1999). However, it eventually 
turns out that tyrosine-phosphorylation in their ligands is not a must for all 
PTB-containing proteins, e.g. XI1, disabled 1 and numb (Dho et al., 1998; Howell et 
al., 1999; Uhlik et al., 2005; Zhang et al., 1997). In addition, PTB domains can also 
bind head groups of phosphatidylinositides, utilizing a different binding motif from 
the one targeting NPXY. Therefore, nearly all PTB-containing proteins can localize 
to membrane or juxtamembrane regions (Uhlik et al., 2005). Up-to-date, almost all of 
the PTB-containing proteins do not have any known catalytic activities; it is likely 
that they generally behave as adaptors and scaffolding proteins. 
The PTB domains in FE65 consist of around 150 residues each, and are both 
classified as Dab-like PTEs, which bind their interactors in a 
phosphotyrosine-independent manner (Uhlik et al., 2005). The one situated more to 
the N-terminal is named PTBl while the other PTB2. The two domains have 
different substrate specificities. For instance, PTB2 binds the cytosolic domain of 
APP targeting its YENPTY motif, which PTBl fails to bind (Borg et al., 1996). It is 
postulated that by binding different ligands at the same time, the two PTB domains 
of FE65 facilitate the assembly of different proteins into multipartite complexes 
(Margolis et al., 1999). An example is the lipoprotein receptor-related protein 1 
(LRP)-FE65-APP complex, in which FE65 binds LRP with its PTBl domain while 
simultaneously binding to APP with its PTB2 domain (Pietrzik et al., 2004). 
1.1.2 Expression Pattern of FE65 Proteins 
The full-length human FE65 protein is expressed at the highest level at the brain, 
particularly the neurons, whereas a low level of expression is observed in other 
tissues (Bressler et al., 1996; Hu et al., 1999). In mouse brain FE65 is detected at the 
highest level in the hippocampus, where the earliest pathological signs of AD are 
observed, as well as in the cerebellum, cortex and the thalamus (Bressler et aL, 1996; 
Kesavapany et al., 2002). Similarly, though less restricted, the expression of human 
FE65L1 and FE65L2 are found to be highest at the brain (Guenette et al., 1996; 
Tanahashi and Tabira, 1999a). 
The expression of the FE65 protein in brain is developmentally regulated. In 
rodents, the mRNA or protein levels of FE65 peak during late embryogenesis, at 
around embryonic day 12.5 to day 15, and then start to decline. Its levels recur 
post-partum and increase steadily until adulthood (Esposito et al., 1990; Kesavapany 
et al., 2002; Simeone et al., 1994). These findings give support that FE65 may have 
important neuronal functions, possibly including, but not limited to, developmental 
regulations (Guenette et al., 2006; Kesavapany et al., 2002; Russo et al., 1998; Sabo 
et al., 2003). 
In cell, endogenous expression of the FE65 protein is both nuclear and 
cytoplasmic (Lee et al., 2008). It is attached to the cytosolic domains of membrane 
receptors, such as APP and LRP, and can undergo translocation into cell nucleus 
(Kesavapany et al., 2002; Minopoli et al., 2001; Trommsdorff et al., 1998). The 
presence of FE65 in both the cytosol and the cell nucleus signifies its importance as a 
scaffolding protein and as a regulator of gene transcription. 
1.1.3 FE65 Family-Transgenic Animals 
In C. elegans, the FE65 orthologue feh-1 is indispensable for survival (Bimonte 
et aL, 2004). Null worms die at the late stage of embyogenesis or during the first 
larval stage. In human, it is postulated that the paralogous FE65 proteins may have 
redundant functions (Guenette et a l , 2006). Single knockout mice of either FE65'^' or 
FE65LrZ_ do not demonstrate lower viability or any obvious histological or 
neruroanatomical defects (Guenette et al., 2006). However, cells from FE65 
knockout mice demonstrate higher sensitivity towards DNA damage induced by 
chemicals or radiations (Minopoli et a l , 2007). In contrast, FE65"^' / FE65Lr" double 
knockout mice show significant increase in neonatal mortality and the viable mice 
display abnormal behaviour, possibly due to defects in neuronal development. 
Anatomical analysis has revealed neuronal heterotopias in the cortex and disruption 
of pial basement membrane during the early embryonic stage (Guenette et al., 2006). 
This phenomenon stresses the role of FE65 in neural development, particularly in 
neuronal migration and positioning. 
In addition, it is reported that when compared to the wild type, FE65-knockout 
mice show no obvious physical or histopathological defects (Wang et al., 2004). 
However they have a significantly impaired performance in tests of learning and 
memory, which suggests the role of FE65 in cognition. 
In another model, double-transgenic mice were bred from the cross of human 
FE65-overexpressing mice and APP751 Swedish-London mutant transgenic mice 
(Santiard-Baron et al., 2005). It is reported that the level of Ap accumulation is 
lowered in the double mice, which emphasizes the role of FE65 in the processing of 
APP (Santiard-Baron et al., 2005). 
1.1.4 Interacting Partners of FE65 
FE65 is considered as an adaptor/scaffolding protein because it can interact with 
a large variety of different partners through its three protein interaction domains 
(Bressler et al., 1996; Guenette et al., 1996; Sudol et al., 2001; Tanahashi and Tabira, 
1999b; Uhlik et al., 2005). Thus FE65 probably involves a large number of different 
cellular processes via interactions with different proteins. The following paragraphs 
summarize some of the established interacting partners of FE65. 
1.1.4.1 APRAPLPl andAPLP2 
The most significant aspect of functions of FE65 involves its ability to influence 
APP processing (Guenette et aL, 2006; Minopoli et al., 2007; Wang et al., 2004). 
Under physiological conditions, the type I membrane-spanning protein APP 
undergoes proteolytic cleavage through both the amyloidogenic pathway and the 
non-amyloidogenic pathway (Burns and Iliffe, 2009; Jakob-Roetne and Jacobsen, 
2009; Price et a l , 2009). By the action of P-secretase and subsequently y-secretase, 
the amyloidogenic pathway yields a secreted APP ectodomain (APPsp), Ap and 
AICD (Jacobsen and Iverfeldt, 2009; Jakob-Roetne and Jacobsen, 2009; Sinha and 
Lieberburg, 1999). This pathway is found to be dominant in secretory and endocytic 
vesicles (Koo and Squazzo, 1994). Thus it is believed that Ap is mainly produced 
through the endocytic pathways (Steiner et al., 1999; Vassar, 2002). Ap deposits in 
intracellular spaces in the brain is the most important hallmark of Alzheimer's 
disease (Di Carlo, 2009; Findeis, 2007; Finder and Glockshuber, 2007). On the other 
hand, a-secretase is believed to perform its function when APP is in the cell 
membrane (Allinson et al., 2003; Hooper et al., 2000). 
As stated earlier, the PTB2 domain of FE65 binds the YENPTY motif on APP in 
a phosphorylation-independent manner (Borg et aL, 1996). The same domain of 
FE65 also binds APLPl (APP-like protein 1) and APLP2 (APP-like protein 2), two 
proteins that are homologous to APP (Bressler et al., 1996). In addition the PTB2 
domains of FE65L1 and FE65L2 both bind the intracellular domain of APP (Duilio 
et al., 1998; Guenette et al., 1996). FE65L1 and FE65L2 also bind APLP-1 and APL2, 
probably through the YENPTY motif (Duilio et al., 1998; Guenette et al., 1996). 
1.1.4.2 LRPl and ApoEr2 
Lipoprotein receptors are heavily linked to the pathological processes in 
Alzheimer's disease through regulation and processing of APP and the production of 
Ap (Andersen and Willnow, 2006). Lipoprotein-related protein (LRPl) is a large type 
I transmembrane glycoprotein with a small C-terminal cytoplasmic tail. It 
participates in a diverse set of functions including regulation of internalization and 
degradation of extracellular ligands, and mediating the processing and trafficking of 
APP (Pietrzik et a l , 2002). It is reported that LRPl binds FE65 through its PTBl 
domain, and is subsequently shown that LRP1-FE65-APP forms a tripartite complex 
and that FE65 can increase APP cleavage only when LRPl is present, by increasing 
its recycling through clathrin-coated endocytosis (Trommsdorff et al., 1998). In 
addition, when FE65 is knocked down, LRPl fails to regulate APP processing 
(Pietrzik et al., 2004). 
ApoE Receptor 2 (ApoEr2) is a relative of LRPl though it has a much smaller 
extracellular domain (A ndersen and Willnow, 2006). It can also bind the PTBl 
domain of FE65 (Hoe et al., 2006). FE65 is reported to affect the processing of 
ApoEr2 and APP in a very delicate manner. The full-length FE65 protein is reported 
to regulate the cleavage of ApoEr2 in a cell-type dependent fashion (Hoe et al., 2006). 
It can secure the interaction between APP and ApoEr2, and increase the cleavage of 
APP, when deprived of LRPl, while the opposite is true when LRPl is expressed 
(Hoe et al., 2006). It is also reported that full-length FE65 can reduce Ap42 level in 
cells overexpressing APP and APoEr2 (Hoe et a l , 2006). 
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1.1.4.3 c-Abl 
c-Abl is a proto-oncogenic non-receptor tyrosine kinase that can translocate into 
the nucleus. It is a member of the Abl proteins. It regulates apoptosis and cell 
survival, cell shape and motility, and is important in neuronal development and 
morphogenesis (Hernandez et al., 2004). 
It is reported that c-Abl can interact with the WW domain of FE65 domain and 
AICD, in addition to phosphorylating them, resulting in modifications of their 
subcellular distributions and enhancement of the transcription activity of the complex, 
e.g. on glycogen synthase kinase (GSK3p) (Perkinton et a l , 2004; Zambrano et al., 
2001). c-Abl is also required for the apoptotic response induced by FE65 (Vazquez et 
al., 2009). 
1.1.4.4 Mena and EVL 
In Dwsophila, mutations of homologues of the proto-oncogene Abl, which 
encodes for a non-receptor tyrosine kinase, disrupt the formation of axons in the 
CNS and the attachment of muscles to the body cell wall in embryos (Hoffmann, 
1991). Enabled (Ena) is a gene later found to alleviate the Abl phenotype (Gertler et 
al., 1995). The mammalian homologue of Enabled is called Mena, which is 
structurally related to another protein Ena-VASP-like (EVL) (Krause et a l , 2003). 
These proteins belong to the family of Ena/VASP proteins, which are located at 
leading edge of lamellipodia, tips of filopodia, focal adhesions and actin stress fibers 
(Krause et al., 2003). They are regulators of actin cytoskeleton, cell migration and 
axonal guidance (Reinhard et al., 2001). One i so form of Mena is neuronal-specific 
and is implicated in the migration of neurons during development (Goh et al., 2002; 
Lanier et al., 1999). 
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The WW domain of FE65 can bind these two proteins through their proline-rich 
motifs (Ermekova et al., 1997; Lambrechts et al.’ 2000). These interactions probably 
contribute to the regulation of cell motility by FE65 with APP (Sabo et al., 2001). 
1.1.4.5 Tip60 
Tip60 is a lysine acetyltransferase that exists in three isoforms (Sapountzi et al., 
2006). It can acetylate core histories, transcription factors and kinases; thus 
regulating chromosome structure and gene expression (Kimura and Horikoshi, 1998; 
Tang et a l , 2006). Most cellular Tip60 exists as part of a large stable nuclear 
multiprotein complex and performs transcriptional, DNA damage signaling and 
apoptotic functions (Sapountzi et a l , 2006; Squatrito et al., 2006). It is reported that 
Tip60 can bind the PTBl domain of FE65 (Cao and Sudhof, 2001), forming a highly 
transactive ternary complex with AICD, when the bound FE65 is a full-length one. 
Two identified targets of the Tip60/FE65/AICD complex is the promoter of the gene 
involved in suppression of cancer metastasis, KAIl, and that of neprilysin, a protease 
that can degrade Ap (Back et al., 2002; Liu and Zhang, 2006; Pardossi-Piquard et a l , 
2005). 
1.1.4.6 SET 
It is later reported that SET, a nucleosome assembly factor, also participates in 
the formation of this complex, by binding FE65 at a site partially contributed by the 
WW domain. The activity of FE65 transactivation is dependent on the presence of 
SET (Telese et al., 2005). 
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1.1.4.7 Estrogen Receptor a 
Estrogen receptors are zinc finger-containing transcription factors that belong to 
the steroid/thyroid nuclear receptor superfamily (Katzenellenbogen, 1996; 
Katzenellenbogen et al., 2000). Upon ligand binding, ER forms homodimer and 
binds the estrogen response element. By recruiting transcriptional machineries, the 
complex activates gene transcription (Klinge et al., 2004). In addition to regulation of 
reproductive systems, estrogen mediates neuronal activities and plays a 
neuroprotective role, e.g. against AD and ischemic injury (Goodenough et al., 2003; 
Wise et al.,2001). 
Estrogen inhibits transcriptional activity and apoptosis induced by AICD 
transcriptional complex, through the interaction between estrogen receptor a (ERa) 
and FE65 (Bao et al., 2007). By binding FE65, estradiol can inhibit induction of 
target genes of the AICD-FE65-Tip60 complex, including KAIl. It also alleviates 
apoptosis in cells through the activation of caspase 4 by the AICD complex. 
1.1.4.8 Teashirt 
Teashirt is a family of zinc finger homeobox. It can interact with certain histone 
deacetylases to repress gene expression (Singh et al., 2002; Wu and Cohen, 2002). It 
is reported that the PTBl domain of FE65 can bind all Teashirt proteins (Kajiwara et 
a l , 2009). The interaction can suppress the transactivity of FE65 on specific targets, 
such as the CASP4 gene, which codes for the inflammatory caspase-4 (Kajiwara et 
al., 2009). 
1.1.4.9 CP2/LSF/LBP1 
CP2/LSF/LBP1 is a known transcription factor, which has been reported to 
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influence a variety of cellular functions including binding onto the murine a-globin 
promoter and the SV40 promoter (Lim et al., 1992; Shirra et a l , 1994). 
CP2/LSF/LBP1 binds the PTBl domain of FE65, both inside the nucleus and in the 
cytosolic fraction (Zambrano et a l , 1998). It is reported that CP2/LSF/LBP1 forms a 
tripartite complex with FE65 and AICD, which reduces the expression level of 
P-catenin but induces GSK-3p and subsequently Tau phosphorylation (Kim et al., 
2003). 
1.1.4.10 Dexrasl 
Dexrasl is a dexamethasone-induced small Ras protein, which is expressed in 
the hippocampus, thalamus and hypothalamus (Takahashi et a l , 2003). Dexrasl is 
implicated in cell signaling. It can stimulate Gj heterotrimeric G protein independent 
of receptor activation, in addition to blocking heterologous sensitization of adenylyl 
cyclase 1 and suppressing cell growth (Cismowski et al., 2000; Nguyen and Watts, 
2005; Vaidyanathan et al., 2004). It is also responsible for downstream signaling of 
several receptors (Graham et al., 2002; Nguyen and Watts, 2005). 
Dexrasl binds the PTB2 domain of FE65, forming a tripartite complex with 
APP (Lau et al., 2008). The binding of Dexrasl significantly reduces the transactivity 
of the FE65-APP complex. One of the target genes downregulated by dexrasl is 
GSK3p, which facilitates Tau phosphorylation. 
1.1.4.11 P2X2-receptor subunit 
P2X receptors are plasma membrane-bound ionotropic purine-activated 
receptors (Burnstock, 2007). They are activated by extracellular ATP and are 
organized as a multimeric complex. In neuronal tissues P2X receptors are important 
14 
in synaptic transmission. There are seven isoforms and the P2X2 receptor is mainly 
distributed in smooth muscles and CNS. 
The WW domain of FE65 is shown to interact with P2X2 receptors at excitatory 
synapses, regulating its synaptic functions (Masin et al., 2006). 
1.1.4.12 Tail 
Tau is a microtubule-binding protein implicated in morphogenesis of neurons, 
axonal growth and guidance and axonal transport (Kempf et al., 1996; Liu et al., 
1999; Stamer et al., 2002). It is strongly linked to AD since hyperphosphorylated Tau 
forms neurofibrillary tangles, the second hallmark of AD (Wood et al., 1986). The 
phosphorylation of Tau is modulated by many kinases, including GSK-3p and cdk5 
(Gendron and Petrucelli, 2009; Michel et a l , 1998) 
The PTBl domain of FE65 binds Tau, forming a ternary complex with APP 
(Barbato et al., 2005). This affinity is repressed by phosphorylation of Tau, but 
requires intact microtubule network (Barbato et al., 2005). 
1.1.4.13 Notch 1 
Notch 1 is a type I transmembrane protein important in cell fate determination 
and morphogenesis, e.g. neurogenesis and axon guidance (Le Gall et a l , 2008). The 
Notch 1 signaling pathway and the APP processing are found to have crosstalks. For 
example, both are cleaved by y-secretase, releasing the intracellular domain (De 
Strooper et al., 1999). Notch 1 releases the Notch intracellular domain (NICD) upon 
ligand binding, such as by delta-like protein 1 (Dill), and then translocates into the 
nucleus for transcriptional regulations. In high analogy, APP undergoes y-secretase 
cleavage to release AICD, which is also transcriptionally active. 
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It is reported that Notch 1 can bind FE65, while at the same time both the 
intracellular and extracellular domains of Notch 1 have direct interaction with APP, 
independent of FE65 (Fischer et al., 2005). 
1.1.4.14 Alcadein 
Alcadeins (Ale) are type I transmembrane proteins that have a similar 
receptor-like structure as APP (Araki et al., 2003). Like APP, Ale can undergo 
proteolytic cleavage to release its ectodomain into the extracellular matrix. By 
further undergoing y-secretase cleavage, Ale can produce the Ale intracellular 
domain (Ale ICD), which is analogous to the production of AICD (Araki et al., 2004). 
In addition, Ale can regulate APP metabolism by forming a tripartite complex with 
APP and XI IL (Araki et a l , 2003). 
Ale, through its NPMETY motif, can bind FE65 and compete against the 
APP-FE65 interaction (Araki et al., 2004). The Alc-FE65 interaction facilitates the 
nuclear-localization of Ale ICD, which is similar to the nuclear translocation of 
APP-FE65 (Kinoshita et al., 2002b). The Alc-FE65 interaction is shown to suppress 
the transactivity of the APP-FE65 complex (Araki et al., 2004). 
1.1.4.15 CD95/Fas/Apo-l ligand 
CD95/Fas/Apo-l ligand (CD95L or FASL) is a transmembrane protein that 
serves as a ligand for CD95/FAS/Apo-l and induces apoptosis in cells, such as 
lymphocytes (Ju et al., 1995). It can also act as a signaling receptor in regulating cell 
cycle and cell proliferation in some cells (Suzuki and Fink, 1998). 
CD95L contains a polyproline region which demonstrates strong affinities 
towards the SH3 or WW modules (Wenzel et al., 2001). A GST-pull down assay 
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showed that wild type FE65 WW domain showed strong interaction towards CD95L. 
1.1.4.16 p68 subunit of pre-mRNA cleavage and polyadenylation factor Im (p68 
CFIm) 
p68 CFIm is encoded by the gene CPSF6, and is required for the 3’ RNA 
cleavage and polyadenylation processing (Millevoi et al., 2006). In an attempt to 
identify and characterize human WW domain-binding partners, it is found that the 
proline-rich region of p68 CFIm can bind the WW domain of FE65 (Ingham et al., 
2005). • 
1.1.4.17 Ataxinl 
Ataxinl is linked to autosomal dominant spinocerebellar ataxia, which are a 
group of neurodegenerative disease characterized by the expansion of CAG repeats 
in the disease proteins (Honti and Vecsei, 2005; Uchihara et a l , 2006). Ataxinl 
interacts with a transcriptional corepressor and histone deacetylase 3. It can bind 
chromosomes and mediate transcriptional repression (Tsai et al., 2004). In a yeast 
two hybrid screen using ataxinl as bait, FE65 is shown to be its interactor (Lim et al., 
2006). 
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Table 1 Summary of interactors of FE65 
Interactor FE65 
Domain 
Brief Description References 
Mena WW This protein is the mammalian orthologue 
of the Drosophila Enabled. It is a 
cytoskeleton regulatory protein involved in 




EVL WW This protein belongs to the same family as 
Mena. It is also a regulator of actin 
cytoskeleton and cell migration. 
(Lambrechts 
et a l , 2000) 
c-abl WW This proto-oncogene encodes a non-receptor 
tyrosine kinase that is involved in cell 
differentiation, cell division, cell adhesion 





WW This transmembrane protein is a ligand for 
FAS. Its interaction with FE65 is critical in 
triggering apoptosis in lymphocytes. 
(Wenzel et al., 
2001) 
p68 CFIm WW p68 is a subunit necessary for pre-mRNA 
processing. Its proline-rich sequence is 
shown to bind FE65. 
(Ingham et al., 
2005) 
SET WW This nucleosome assembly protein is one of 
the main components of inhibitor of histone 
acetyltransferase. It is also functionally 
linked to the FE65/AICD/Tip60 complex. 




WW The ionotropic P2X2 receptor can interact 
with other neurotransmitter receptors and 
regulate synaptic transmission plasticity. 




protein 1 (LRPl) 
PTBl This protein is a neuronal surface receptor 
that is genetically linked to Alzheimer's 
disease. 
(Trommsdorff 
et al., 1998) 
Tip60 PTBl This protein is a histone acetyltransferase 
that has a role in DNA repair and apoptosis 




CP2/LSF/LBP1 PTBl This encodes a nuclear transcription factor 
that regulates the expression of A2M and 
glycogen synthase kinase-3p. 
(Kim et al., 
2003) 
Tau PTBl Hyperphosphorylated Tau accumulates as 
neurofibrillary tangle, which is the second 
pathological hallmark of AD. It binds the 




ApoEr2 PTBl This protein is another apoE receptor. It also 
interacts with APP and modulates APP 
processing. 
(Hoe et al., 
2006) 
Teashirt PTBl This protein can recruit histone 
deacetyltransferases to silence gene 
expression. 
(Kajiwara et 





PTB2 This transmembrane cell surface receptor 
can undergo proteolytic cleavage to produce 
peptides responsible for the formation of 
amyloid plaques in brains of Alzheimer's 
disease. 




protein 1 and 2 
PTB2 These proteins are members of the highly 
conserved APP protein family 
(Bressler et 
al., 1996) 
Dexrasl PTB2 This protein is a Ras-related protein that is 
involved in cell morphology, growth and 
cell-extracellular matrix interactions. 
(Lau et al., 
2008) 
Alcadein (Ale) Unknown Ale is a type I transmembrane protein 
similar in structure and metabolism to APP. 
Its binding to FE65 down-regulates the 
transactivation of the FE65-AICD complex. 
(Araki et a l , 
2004) 
Notch 1 Unknown Notch 1 is a type I transmembrane protein 
important in morphogenesis and cell fate 
determination. It is shown to bind FE65. 
(Fischer et al., 
2005) 
Ataxinl Unknown Ataxinl is implicated in transcriptional 
control of genes, and is related to 
spinocerebellar ataxias. It is shown to 
interact with FE65 in a yeast two hybrid 
screen. 




Unknown ERa is a transcription factor. It binds FE65 
and suppresses the transactivity of 
AICD-FE65 complex. 
(Bao et al., 
2007) 
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1.1.5 Functions of FE65 
1.1.5.1 FE65 as an adaptor protein 
All the three domains of FE65, the WW domain and the two PTB domains are 
well-known structural modules for establishing protein-protein interactions (Margolis 
et al., 1999; Sudol et al., 2001; Uhlik et al.，2005). FE65 enables the formation of 
multimodular complexes, by allowing one domain bind a ligand while the remaining 
domains bind the others, as in the case when FE65 acts as the physical link between 
APP and LRPl (Pietrzik et al., 2004). In addition, FE65 is the 'bridge' that connects 
membrane bound APP to the cytoskeleton through its interaction with Mena. Finally, 
FE65 forms complexes with AICD as well as a large number of transcriptional 
activators to perform its diverse roles on gene expression. In contrast, some domains 
of FE65, such as PTB2, are reported to accommodate more than one ligand at a time, 
as in the protein complex APP-FE65-Dexrasl (Lau et al., 2008). 
1.1.5.2 FE65 and Alzheimer's disease 
FE65, being an important adaptor protein that binds APP, is generally believed 
to alter APP processing and thus plays a pivotal role in AD. However, the effects of 
regulation on APP processing by FE65 are still controversial. Initially, in 
Madin-Darby canine kidney cells, the FE65-APP interaction is reported to enhance 
APP translocation to the cell surface, thus increasing both APPs and Ap (Sabo et al., 
1999). Yet, in HEK293 cells, it is later reported that FE65 actually slightly suppresses 
APP maturation and reduces the production of Ap (Ando et a l , 2001). Interestingly, 
FE65L1 and FE65L2 are both amyloidogenic, in H4, a human neuroglioma cell line, 
and HEK293, respectively (Chang et al., 2003; Tanahashi and Tabira, 2002). 
In a transgenic model, the overexpression of human FE65 reduces the Ap level 
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in a mouse expressing APP751 Swedish double mutation (K670N and M671L) and 
the London mutation (V717I) (Santiard-Baron et al., 2005). In contrast, the primary 
neurons from a transgenic mouse expressing APPsw (the Swedish mutation) secreted 
Ap42 in an amount inversely correlated to the degree of knockout (partial or total 
knockout) of FE65 (Wang et a l , 2004). In another transgenic model where both 
FE65 and FE65L1 were knocked out, the adult male mice had a reduction in brain 
A(3 level, though this is not observed in the female littermates (Guenette et a l , 2006). 
Furthermore, the interaction between FE65 and APP is more complicatedly 
regulated. In neurons, mature APP695 is phosphorylated specifically at T-688 (lijima 
et al., 2000). In HEK293 cells, this T668 phosphorylation reduces the affinity 
between FE65 and APP by imposing a conformational change in the downstream 
YENPTY motif (Ando et al., 2001). The Swedish mutation of APP770 is also reported 
to reduce its affinity towards FE65 (Zambrano et al., 1997). 
It is also reported that overexpression of FE65 in CHO cells reduces APP CTF 
levels and sAPP. However this action can be reversed by the elimination of LRP 
(Hoe et al., 2006). In contrast, full-length FE65 promotes the production of APP CTF 
and sAPP in C0S7 cells. 
The apparent controversy or contradiction among these data may lead to the 
conclusion that even though FE65 binds APP under most conditions, its regulation on 
APP processing or Ap production is probably dependent on many factors, such as 
sources and types of cell lines, sex of test subjects or hormonal environment, relative 
levels of different isoforms of FE65, the availability and phosphorylation state of 
APP or other interacting proteins (McLoughlin and Miller, 2008). These may all have 
subtle effects on the action of FE65 upon the trafficking, processing or ligand 
preference, which may in turn have profound influences on AD. 
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1.1.5.3 Transcriptional / Post-transcriptional regulation 
FE65 was long expected to participate in transcriptional regulation of genes ever 
since its discovery due to its partial similarity with retroviral integrases (Duilio et al., 
1991). In addition, the WW domain is also reported to bind nuclear proteins 
performing transcriptional functions (Sudol et al., 2001). It is reported that FE65 can 
stabilize AICD and translocate inside the nucleus as a transcriptionally active 
complex (Cao and Sudhof, 2001; Kimberly et a l , 2001; Yang et al., 2006). 
The FE65-AICD-dependent transactivation can be modulated by many different 
interactors. c-Abl phosphorylates FE65 and augments the transcription of FE65-APP 
complex (Perkinton et a l , 2004). CP2/LSF/LBP1, a transcription factor, binds the 
FE65-APP complex, reducing p-catenin yet inducing GSK-3p level ((Kim et al., 
2003; Zambrano et al., 1998). In contrast, Dexrasl is a repressor of FE65-APP 
transactive complex and can inhibit GSK-3p transcription (Lau et al., 2008). The 
complicated regulation of FE65-APP complexes on GSK-3p level relates APP with 
the other hallmark of AD, since GSK-3P is responsible for phosphorylation of Tau 
(Michel et al., 1998). The histone acetyltransferase Tip60 binds FE65 and AICD to 
form a less transactive complex, which induces neprilysin and regulates KAIl 
expression together with the nucleosome assembly factor SET (Back et al., 2002; 
Cao and Sudhof, 2001; Pardossi-Piquard et a l , 2005; Yang et a l , 2006). Neprilysin is 
an endopeptidase capable of degrading Ap, while the transcriptional regulations of 
p-catenin and KAIl provides further emphasis on the role of APP and FE65 in cell 
adhesion and cell motility (Mohajeri et a l , 2002; Yang et al., 2008). 
It is demonstrated that FE65-AICD-induced transcription is regulated by the 
phosphorylation state on APP (Chang et al., 2006). Interestingly, AICD expression 
alone was autoregulatory (von Rotz et al., 2004). It can induce the expression of APP, 
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BACE and Tip60, though the fold increase is not as strong as when FE65 is present. 
Finally, it is worth-noting that FE65L1 and FE65L2 fail to form a transcriptionally 
active complex with AICD (Chang et a l , 2003; Tanahashi and Tabira, 2002). 
1.1.5.4 Apoptosis and cell cycle regulation 
APP is related to cell proliferation or cell death in several aspects. It can 
undergo proteolytic processing by group III caspases, including capspase-6, 
caspase-8 and caspase-9 (Weidemann et al., 1999). In addition, AICD can induce 
apoptosis in neuronal cells through transcriptional induction of p53 and activation of 
caspase-3 (Alves da Costa et al., 2006; Kinoshita et al., 2002a; Nakayama et a l , 
2008). Phosphorylation of APP and binding of FE65 are reported to enhance 
AICD-induced apoptosis (Chang et al., 2006). On the other hand, 17P-estradiol 
rescues the caspase-3 activation induced by the AICD complex (Bao et al., 2007). In 
fact, overexpression of FE65 alone is apoptotic, which can be further enhanced by 
c-Abl or APPsw overexpressions (Vazquez et a l , 2009). It is reported that the 
overexpression of FE65 can also stop cell cycle progression by abolishing the 
expression of thymidylate synthase, which is activated by CP2/LSF/LBP1 (Bruni et 
a l , 2002). Interestingly, this cell cycle blockage can be reversed by wild type APP 
overexpression. Finally, cells from FE65 knock-out mice show significantly higher 
sensitivity to insults that cause DNA damage (Minopoli et al., 2007). All these 
phenomena give support that FE65 is a pro-apoptotic protein. 
1.1.5.5 Neuronal positioning and cell migration 
The expression level of FE65 is developmentally-regulated (Kesavapany et al., 
2002). The FE65 and FE65L1 double knockout mice have much lower viability than 
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their wild type littermates, and their brains show histological malformations in both 
the embryonic and adult stages (Guenette et al., 2006). Significant neuronal ectopias 
were observed since cortical development, where neurons were overmigrated. In 
addition, the meningeal fibroblasts from these mice show reduced laminin but 
increased F-actin fiber thickness. These aberrations are not due to changes in APP 
processing, thus emphasize the role of FE65 in neuronal development. 
In fact, the APP protein family is implicated in cell adhesion, since APP binds 
type I collagen, laminin, integrins, fasciclin II and heparin sulfate proteoglycan 
glypican-1 (Kibbey et al., 1993; Yamazaki et al., 1997; Ashley et al., 2005; 
Williamson et al., 1996). In addition, Mena and EVL, which bind the WW domain of 
FE65, are members of the Ena/VASP family of actin cytoskeleton regulatory proteins, 
which are implicated in cell migration (Krause et al., 2003). APP, FE65 and Mena 
colocalize at neuronal growth cones in vitro and in vivo (Sabo et al., 2003), where 
APP and FE65 are highly concentrated at the P domains, which are known to be 
enriched in dynamic actin filaments. Furthermore, APP and FE65 colocalize and 
form complexes at the neuronal synapses, possibly contributing to functions such as 
synapse formation and synaptic plasticity. 
Experimental evidence shows that in cells, APP, FE65 and Mena form a 
complex and colocalize at the dynamic, cotactin-rich lamellipodia and the focal 
complexes, which are important during cell movements; yet they are not observed at 
the stable focal adhesions on cell surface (Sabo et al., 2001). In addition, 
FE65-APP-transfected cells demonstrate significantly greater rate of cell movement 
than cells with either single transfection. Finally, KAIl, a protein important in cell 
adhesion and cancer metastasis, is transcriptionally induced by the FE65-AICD 
complex. These findings all provide evidence that FE65-APP is involved in the 
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regulation of cell movement. 
1.1.5.6 Learning and memory 
FE65 is found in high expression level in the hippocampus and cerebral cortex, 
and is probably involved in high-level neuronal functions including learning and 
memory (Kesavapany et al., 2002). This is reflected from the fact that FE65 regulates 
APP and has strong links to AD, which impairs cognitive functions such as memory. 
FE65-knockout mice display cognition deficits. They demonstrate impaired passive 
avoidance learning, while simultaneously showing deficiency in unlearning old 
information (Wang et al., 2004). 
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1.2 Objectives 
FE65 is a brain-enriched adaptor protein that is involved in many cellular 
processes (Dressier et al., 1996; McLoughlin and Miller, 2008; Trommsdorff et al.， 
1998; Yang et al., 2006). However, its precise roles in cells are still not entirely 
known. In this project I have attempted to identify novel FE65-interacting proteins in 
the hope of improving our understanding of FE65. From literature review, I have 
found a number of potential links between FE65 and a small GTP-binding protein 
Arf6. Firstly, both Arf6 and FE65 are involved in the regulation of cell movement or 
cell motility (Sabo et al., 2001; Svensson et al., 2008). Secondly, effectors and 
homologues of Arf6 are regulators of APP trafficking and processing, while FE65 
binds and influences APP processing (Ando et al., 2001; Guenette et al., 2006; Nixon, 
2004; Sabo et al., 1999; Santiard-Baron et al., 2005; Tesco et al., 2007). Furthermore, 
it is recently reported that FE65 can bind a small GTP-binding protein Dexrasl (Lau 
et al., 2008). Finally, it has been shown that Arf6 and its homologues can bind 
PTB-domain containing proteins, and FE65 contains two PTB domains (Ma et al., 
2007; Radzimanowski et al., 2008a; Radzimanowski et al., 2008b; 
Shrivastava-Ranjan et al., 2008). The above information prompted me to test if FE65 
interacts with Arf6, which is one of the aims of this project. GST-pull down and 
immunoprecipitation assays were performed to verify the interaction. 
The second aim of this study is to generate Arf6 antibodies. Our laboratory has 
tested several commercially available anti-Arf6 antibodies but the potencies of these 
antibodies are not sufficient for the detection of endogenous Arf6. In order to 
facilitate our future studies, polyclonal anti-Arf6 antisera were produced in this 
project. 
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Chapter 2 Investigation of the interaction between FE65 and Arf6 
2.1 Materials 
2.1.1 DNA contructs 
The plasmids pEGFP-Arf6 WT and pXS-Arf6 WT HA were generous gifts from 
Dr. J.G. Donaldson and Dr. Ming Bai (Li et a l , 2007; Radhakrishna and Donaldson, 
1997). The plasmids pcDNA-Arf6 WT myc/his, pCMV Tag 2B-Arf6 WT and 
pGEX-6p-l-Arf6 WT, pCI neo-GST, pCI neo-GST-FE65 WW (aa 248 - 290), pCI 
neo-GST-FE65 PTBl (aa 361 - 514)，pCI neo-GST-FE65 PTB2 (aa 531 - 676) were 
generated in our laboratory from other studies. It should be noted that all 
Arf6-enconding plasmids except pCMV Tag2B-Arf6 WT and pGEX-6p-1 -Arf6 WT 
are tagged with a C-terminal tag. 
The above plasmid constructs were purified from Escherichia coli {E .coli) 
DH5a strain using DNA-spin Plasmid DNA Extraction Kit (Intron Biotechnology) 
and NucleoBond Xtra Midi kit (Macherery-Nagel). 
2.1.2 Cell culture 
CHO-Kl and C 0 S 7 cells were obtained from ATCC. Hyclone Dulbecco's 
Modified Eagle's Medium (DMEM) Low Glucose with L-Glutamine and sodium 
pyruvate, Hyclone HAM's/F12 medium and Hyclone fetal bovine serum were 
purchased from Thermo Fisher Scientific. OPTIMEM medium, Trypsin-EDTA and 
Penicillin-Streptomycin were purchased from Invitrogen. FuGENE6 was purchased 
from Roche. PBS tablets were purchased from Sigma. 
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2.1.3 Immunoblotting 
The Mini-Protean System, the Mini Trans-Blot Electrophoretic Transfer Cell 
and 30% Acrylamide/Bis were purchased from Bio-Rad. Ammonium persulfate was 
purchased from USB Chemicals. N,N,N,N-tetramethylethylenediamine (TEMED) 
was purchased from Sigma. Hybond ECL Membrane and Amersham ECL Western 
Blotting Reagents were purchased from GE Healthcare. Medical X-ray Film Super 
RX was purchased from FUJIFILM. 
Antibodies were purchased as follows: Monoclonal mouse anti-FLAG M2 
antibody: Sigma. Monoclonal mouse anti-Myc 9bl l antibody: Cell Signaling 
Technology. Monoclonal mouse anti-Arf6 antibody was purchased from Santa Cruz. 
Anti-Mouse IgG HRP, anti-Rat IgG HRP, anti-Rabbit IgG HRP were purchased from 
GE Healthcare. Anti-FE65 was as described (Lau et al.’ 2000). 
2.1.4 Miscellaneous 
The chemical reagents Tris, Sodium dodecyl sulphate (SDS) and NaCl were 
purchased from USB. Tryptone was purchased from Oxoid. Bacto yeast extract and 
Bacto agar were purchase from Beckton Dickinson. Agarose was purchased from 
Biowest. NaOH was purchased from Mallinckrodt. Absolute methanol was 
purchased from International Laboratory. Absolute ethanol and MnCl2-2H20 were 
purchased from Merck. Concentrated acetic acid and isopropanol were purchased 
from Scharlau. Concentrated HCl and CaCl2-2H20 were purchased from Riedel-de 
Haen. KCl and Coomassie Blue were purchased from BDH. Triton X-100, EDTA 
Disodium salt, Tween-20, Bromophenol blue, glycerol, P-mercaptoethanol and 
ampicillin (used at working concentration 100 |ig/ml.) were purchased from Sigma. 
Complete Protease Inhibitor Cocktail tablets were purchased from Roche. Ethidium 
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bromide was purchased from Bio-Rad. Skimmed milk was purchased from Nestle. 
2.2 Methods 
2.2.1 Preparation of Escherichia coli competent cells 
The DH5a (DE3) strain of E. coli was streaked directly from -70°C frozen stock 
onto a Luria-Bertani Broth (LB) agar plate (10 g/L NaCl, 10 g/L tyrptone, 5 g/L 
Bacto yeast extract, 1% (w/v) Bactor agar) and incubated overnight at 37°C. A single 
colony was picked from the plate and inoculated to 100 ml LB (10 g/L NaCl, 10 g/L 
tyrptone, 5 g/L Bacto yeast extract). The medium was then incubated at 37°C with 
vigorous shaking until ODeoo reached 0.45. The culture was chilled on ice for 15 min. 
The cells were collected by centrifugaion at 1,000 g for 15 min at 4°C. The cell pellet 
was resuspended in 37 ml TFBl (30 mM Potassim Acetate, 50 mM MnCb, 100 mM 
KCl, 10 mM CaCb, 15% Glycerol, adjusted to pH 5.8 with acetic acid, filter 
sterilized) and kept on ice for 15 min at 4°C. The bacterial suspension was 
transferred to another centrifuge tube and collected by centrifugation at 1,000 g for 
15 min at 4°C. The cell pellet was resuspended by 8 ml TFB2 (10 mM MOPS, 75 
mM CaCls, 10 mM KCl, 15% Glycerol adjusted to pH 6.8 with NaOH, filter 
sterilized) and kept on ice for 15 min. The cell suspension was divided into aliquots 
of 100 |xl on dry ice. The transformation efficiency of the competent bacterial cells 
was tested to be 1.9x10^ colonies/|ag DNA using pUC19 for transformation. The 
competent cells were stored at 70°C for later use. 
Competent cells of other strains of E. coli, such as Rosetta 2 (DE3), were 
prepared according to the same protocol. 
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2.2.2 DNA preparation with Intron PI asm id DNA 
A single colony was picked from a streaked LB agar plate with appropriate 
antibiotics and then grown overnight at 37°C in 5 ml LB with appropriate antibiotics. 
The bacterial cells were collected by centrifugation at 16,000 g for 1 min in a 
microcentrifuge tube. The medium was discarded before resuspension with 250 \l\ 
Resuspension buffer added with RNase. After thorough resuspension, 250 nl Lysis 
buffer was added to the suspension and incubated for 5 min at room temperature. 
Three hundred fifty microlitres Neutralization Buffer was then added to the solution 
and mixed by inverting. The suspension was then centrifuged at 16,000 g at room 
temperature for 10 min. The supernatant was extracted and added to the 
DNA-binding column and then centrifuged at 16,000 g for 1 min at room 
temperature. Seven hundred microlitres of Washing buffer B was added to the 
column, which was then centrifuged at 16,000 g for 1 min at room temperature. The 
column was centrifuged for a second time at 16,000 g for 1 min at room temperature 
to dry the membrane in the column. Fifty microlitres autoclaved Nano H2O was 
added to the centre of the membrane and the column was centrifuged at 16,000 g for 
1 min. The eluted DNA solution was quantified by UV spectrometry at 260/280 nm. 
Its integrity was checked by gel electrophoresis. 
2.2.3 DNA preparation with Macherey-Nagel NucleoBond Xtra Midi 
A single colony was picked from a streaked LB agar plate with appropriate 
antibiotics and then grown overnight at 37°C in 200 ml LB with appropriate 
antibiotics. The bacterial cells were collected by centrifugation at 5,500 g for 5 min 
at 4°C in a centrifuge bottle. The medium was discarded before resuspension with 8 
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ml Buffer RES (with RNase). After thorough mixing, 8 ml of Buffer LYS was added 
to the suspension and incubated at room temperature for 5 min. Eight millilitres 
Buffer NEU was added to the suspension and mixed by inverting. The NucleoBond 
Xtra column and the column filter were equilibrated by adding 12 ml Buffer EQU to 
the rim of the filter. The solution flowed through the column by pure gravity. All of 
the neutralized cell lysate suspension is applied to the column and the filter. The 
column and the filter were then washed with 5 ml Buffer EQU. The filter was then 
discarded together with the cell debris. The column was further washed with 8 ml 
Buffer Wash. The DNA was then eluted with 5 ml Buffer ELU into a 15 ml 
centrifuge tube. Subsequently, 3.5 ml isopropanol was added to precipitate the eluted 
DNA. The suspension was then applied to the NucleoBond Finalizer through a 30 ml 
syringe. Two millilitres 70% ethanol was added to wash the precipitated DNA. The 
DNA was then dried by using the syringe to pass air through the Finalizer five times. 
Finally, 200 j^ l Buffer TRIS was added to the Finalizer through a 10 ml syringe to 
dissolve the DNA. To ensure complete elution of the DNA, the solution was applied 
to the Finalizer three times. The eluted DNA was then quantified by UV 
spectrometry at 260/280 nm. Its integrity was checked by gel eletrophoresis. 
2.2.4 DNA preparation by the alkaline lysis method 
A single colony was picked from an LB agar plate and inoculated in 2 ml LB 
culture and incubated at 37°C overnight with shaking. The bacterial cells were 
collected by 16,000 g for 1 min at room temperature. The medium was discarded and 
the cell pellet was resuspended with 0.3 ml Buffer PI (50 mM Tris, 10 mM EDTA, 
adjusted to pH 8.0 with HCl). The cell suspension was lysed with Buffer P2 (200 
mM NaOH, 1% w/v SDS) for 5 min at room temperature after mixing by inversion. 
31 
The lysate was then neutralized with Buffer P3 (2.55 M Potassium acetate, pH 
adjusted to 4.8 with NaOH), mixed by inversion and centrifuged at 16,000 g at room 
temperature for 15 min. The supernatant was then extracted and added with 0.45 ml 
isopropanal and centrifuged at 20,000 g 4°C for 30 min. The supernatant was 
discarded and the precipitated DNA was washed with 1 ml 70% ethanol and mixed 
by vortexing vigorously. The DNA pellet was collected by centrifugation at 16,000 g 
for 5 min at room temperature and the supernatant was discarded. The pellet was 
allowed to dry for 5 min before dissolving in 30 \i\ TE-RNase (100 |ig/ml RNase, 10 
mM Tris, 1 mM EDTA, adjusted to pH 7.4 by HCl). The DNA samples were 
incubated at 37�C for 15 min for RNA degradation before storage or further 
experimentations. 
2.2.5 Spectrophotometric analysis of DNA 
Concentration of the prepared DNA samples was determined with a UV 
spectrophotometer (Beckman Coulter DU 640) at 260 nm and 280 nm. Autoclaved 
Nano H2O was used as blank. A reading of 1.0 at OD260 corresponds to 50 |ig/ml 
double stranded DNA. The purity of DNA was determined by the ratio of readings at 
260 nm to 280 nm. DNA with a high purity should have the ratio value higher than 
1.8. 
2.2.6 Agarose gel electrophoresis 
DNA was separated by 0.8 to 1.5% Tris-acetate-EDTA (TAE, 4.84 g/L Tris, 0.34 
g/L NazEDTA, 20 mM acetic acid) buffer agarose gel, which was prepared by 
dissolving 0.8 to 1.5% agarose (w/v) in IX TAE, containing 0.5 |ig/ml ethidium 
bromide. The DNA samples were mixed with appropriated amounts of 6X DNA 
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loading buffer (40% sucrose (w/v), 0.25% Bromophenol blue) and H2O to make a 
final concentration of lOX. The samples were loaded into the wells of the gel and 
were electrophoresed under a constant voltage of 85 V. After the Bromophenol blue 
dye has migrated to two thirds of the gel, the DNA bands were observed under Gel 
Doc 2000 (Bio-Rad) and photographs were taken with a Mitsubishi Monochrome 
printer. 
2.2.7 Cell culture and transfection 
C0S7 was maintained in DMEM low glucose supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin. CHO-Kl was maintained in Hyclone 
HAM's/F12 supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Both cell lines were kept at 37°C in a humidified tissue 
culture incubator with 5% CO2. At confluency, the cells were detached from T75 
flask with 1 ml Trypsin-EDTA, replacing one tenth of original amount to maintain 
the cell line. 
For transfection using FuGene 6, 100,000 cells were seeded in each well per ml 
medium without penicillin-streptomycin. The cells were transfected immediately 
after seeding. In brief, FuGENE 6 was diluted with OPTIMEM medium in ration of 
1:30. For every 1x10^ seeded cells, 400 ng DNA was added to 50 [l\ diluted FuGENE 
and then incubated at room temperature for 30 min. The DNA-FuGENE 6 mixture 
was added to the seeded cells in a drop-wise manner. The cells were harvested 48 
hours after transfection. 
2.2.8 Bacterial GST-pull down assay 
Recombinant GST and GST-Arf6 proteins were expressed and purified 
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according to the same protocol as section 3.3.1 In brief, 100 ml induced culture of 
each bacteria expressing GST and GST-Arf6 were collected by centrifugation at 
5,000 g for 6 min. The cells were then resuspended in 6 ml NTEH buffer (500 mM 
NaCl, 20 mM Tris, 5 mM EDTA, pH adjusted to 7.6 with HCl) and lysed by 
sonication with Branson Sonifier 150 at power 4 for 10 sec on ice, three times. The 
bacterial lysates were then centrifuged at 20,000 g for 10 min at 4°C and the 
supernatants were collected. One millilitrel of each protein lysate was then bound to 
100 |il washed Glutathione Sepharose 4 Fast Flow resins at room temperature for 2 
hours. The bound resins were washed with 1 ml washing buffer (50 mM Tris, 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, adjusted to pH 7.6 with HCl) three times, 
and finally resuspended in 100 [l\ washing buffer. A small amount of the suspension 
was resolved in SDS-polyacrylamide gel to estimate the amount of bound proteins. 
FE65-myc transfected CHO-Kl as mentioned earlier onto 6 cm plates. Two 
days after transfection, the cells were washed with PBS and subsequently harvested 
in 0.5 ml ice-cold IPb buffer with a plastic cell scraper. The cell suspension was lysed 
by sonication with Branson Sonifier 150 at power 2 for 5 sec. The suspension was 
centrifuged at 20,000 g for 10 min at 4°C and the supernatant was collected. Two 
hundred twenty microlitres of transfected cell lysate were then added to 50 jig 
GST-Arf6 or GST bound resin and allowed to incubate at 4°C overnight on a rocking 
platform. The resins were washed with 1 ml IPb buffer 3 times before boiling for 10 
min in 30 i^l 2X SDS sample buffer (100 mM Tris pH 6.8, 4% SDS, 0.2% 
Bromophenol blue, 20% Glycerol, 200 mM P-mercaptoethanol), and subsequently 
analysed by Western blotting. 
2.2.9 GST-pull down assay for testing direct interaction between 
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FE65 andArf6 
Recombinant PTBl domain of FE65, GST-FE65 PTBl, was expressed as 
mentioned earlier. One hundred microlitre induced bacterial culture expressing 
GST-FE65 PTBl was collected by centrifugation at 5,000 g for 6 min. The cells were 
then resuspended in 6 ml NTEH buffer (500 mM NaCl, 20 mM Tris, 5 mM EDTA, 
pH adjusted to 7.6 with HCl) and lysed by sonication with Branson Sonifier 150 at 
power 4 for 10 sec on ice, three times. The bacterial lysate was then centrifuged at 
20,000 g for 10 min at 4°C and the supernatant was collected. The GST protein 
which acted as a control was purified in the same manner. The protein lysates were 
each bound to 100 [i\ washed Glutathione Sepharose 4 Fast Flow resins at room 
temperature for 2 hours. The bound resins were washed with PBS three times and 
resolved in SDS-polyacrylamide gel. Roughly 50 i^g of each resin-bound bait was 
added to 50 |ig purified recombinant Arf6 (see section 3.3.1) in a 100 |xl reaction and 
incubated overnight at 4°C. The resins were then washed with 1 ml PBS three times. 
They were subsequently boiled for 10 min in 40 [l\ 2X SDS sample buffer and 
analysed by Western blotting. 
2.2.10 Mammalian GST-pull down assay 
Two days after transfection, CHO-Kl cells were washed once with ice-cold 
PBS. The cells were then harvested in 500 |il IPb buffer (50 mM Tris, 150 mM NaCl, 
1 mM EDTA, 1% Triton X 100 and Protease Inhibitor Cocktail) and briefly sonicated 
with a Branson Sonifier 150 for 5 sec at power 3 on ice. The lysate was centrifuged 
at 20,000 g for 10 min at 4°C. Three hundred microlitres of the supernatant was 
applied to 50 |il Glutathione Sepharose 4 Fast Flow resin slurry (prewashed with 1 
ml PBS) and incubated overnight at 4°C. The beads were washed with 1 ml IPb 
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buffer thrice and boiled in 30 pi 2X SDS sample buffer for Western blotting. 
2.2.11 Immunoprecipitation 
Two days after transfection, the CHO-Kl cells were washed twice with PBS and 
harvested by ice-cold IPb buffer with an amount of 250 |il/10 cm dish. The cells were 
briefly sonicated by Branson Sonifier 150 on ice for 5 sec and then centrifuged at 
20,000 g for 10 min at 4°C. The supernatant was collected and 2 \i\ mouse anti-myc 
monoclonal antibody (9B11) was added to the experiment samples, while no 
antibody was added to the control samples. The samples were incubated overnight at 
4°C on a rocking platform. Twenty microlitres Protein G slurry (prewashed with PBS 
three times) was added to each sample and they were incubated at 4°C for 1.5 hours 
on a rocking platform. The samples were washed by brief centrifugation at 20,000 g 
for 10 sec and removed of supernatant, followed by mixing the beads through 
inversion with 1 ml IPb buffer per sample. After three times of washing, the beads 
were again collected by centrifugation at 20,000 g for 10 sec. Forty microlitres 2X 
SDS Buffer was added to the beads and boiled for 10 min. The samples were then 
ready for analysis by Western blotting. 
2.2.12 SDS-PAGE 
The proteins were analyzed by SDS-PAGE with the Mini-Protean System 
(Bio-Rad). The SDS-PAGE experimented were 8%, 10% or 12% gels. The 
preparation of one separation gel and one stacking gel were performed according to 
Table 2 and Table 3. TEMED was the last ingredient added to the mixture before 
casting the gel on the assembly cassette. 
Protein samples were mixed with 2X Sample Buffer (100 mM Tris, 4% SDS, 
36 
0.2% Bromophenol blue, 20% Glycerol, 15 |j.l/ml P-mercaptoethanol, adjusted to pH 
6.8) to a final concentration of IX and boiled for 10 min. The samples were then 
loaded to the wells of the stacking gel. The gel was run in IX Running Buffer (3.02 
g/L Tris, 18.8 g/L glycine, 1% SDS) at a constant current of 20 mA per gel until the 
Bromophenol blue just reached the brim. For direct visualization of the protein bands, 
the gel was disassembled from the cassette and the stacking gel was sliced off and 
discarded. The separating gel was stained by soaking in Staining Solution (2.5 g/L 
Coomassie Blue R250, 450 ml/L methanol, 100 ml/L acetic acid) for 30 min at room 
temperature. It was subsequently destained by Destainrng Solution (450 ml/L 
methanol, 100 ml/L acetic acid) until the bands were clearly visible. 
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Table 2 Ingredients for preparation of a separating gel 
Gel Percentage 8% 10% 12% 
H2O 1.86 ml 1.55 ml 1.28 ml 
30% Acrylamide 1.07 ml 1.33 ml 1.6 ml 
1.5 MTris pH 8.8 1.04 ml 1.04 ml 1.04 ml 
10%SDS 40 40 40 i^l 
10% APS 40 40 40 
TEMED 6\i\ 6^1 
Table 3 Ingredients for preparation of a stacking gel 
H2O 1.4 ml 
30%Acrylamide 0.33 ml 
IMTris 6.8 0.25 ml 
IQo/oSDS 20 [i\ 




For protein samples that need to be analysed by Western blot analysis, the 
separating gel was transferred to a Hybond ECL membrane by sandwiching the gel 
and membrane between two pieces of 3MM Chromatography Paper (Whatman) and 
placed within Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad). The transfer 
process was performed in an ice-cold environment with chilled Wet Transfer Buffer 
(25 mM Tris, 192 mM glycine, 20% methanol, 0.02% SDS) at a constant voltage of 
100 V per membrane, with a maximum current of 300 mA. The membrane was then 
blocked with TEST (20 mM Tris, 136 mM NaCl, 0.1% Tween-20, adjusted to pH 7.6 
with HCl) supplemented with 5% (w/v) skimmed milk, before probing with primary 
antibodies (1:2,500, unless otherwise stated) in TBST with 5% skimmed milk 4°C 
overnight on a rocking platform. The membrane was then washed with TBST 3 times 
before probing with secondary antibodies (1:2,500, unless otherwise stated) in TBST 
with 5% skimmed milk for 1.5 hours. Enhanced chemiluminescence (ECL) was 
performed with Amersham ECL Western Blotting reagents as instructed by the 
manufacturer's manual, and the blot was exposed to Medical X-ray Film, 
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2.3 Results 
2.3.1 Interaction between Arf6 and FE65 
Bacterial expressed GST-Arf6 was immobilized on glutathione sepharose resins 
and incubated overnight with FE65 transfected CHO-Kl cell lysates. High amount of 
FE65 was pulled down together with GST-Arf6, while a comparable amount of 
immobilized GST protein could not pull down FE65 (Fig 2.1). The result provides 
the first evidence that Arf6 can interact with FE65. 
To test if Arf6 and FE65 interact in mammalian cells, co-immunoprecipitation 
was carried out (Fig 2.2). Arf6-myc and FE65 were cotransfected into CHO-Kl cells. 
The anti-myc antibody 9B11 was used to immunoprecipitate Arf6-myc and its bound 
partners. The presence of FE65 in the immunoprecipitate was revealed using an 
anti-FE65 antibody (Lau et al., 2000). However, FE65 was not observed in the FE65 
singly transfected control, nor in cotransfected cell lysate without the addition of 
9B11. This result suggests that Arf6 and FE65 may interact in vivo. 
In Fig 2.2, when detected with anti-myc antibody, Arf6-myc produced two 
bands of slightly different molecular masses. This is probably due to the fact that 
Arf6 can undergo myristoylation after protein traslation in cell. This phenomenon is 
also observed in reports from other groups (Muralidharan-Chari et al., 2009; Poupart 
et al., 2007). It is also reported that myristoylation can increase molecular mass of a 









Fig 2.1 Bacterial expressed Arf6 interacts with FE65 overexpressed in mammalian 
cells. Bacterial expressed GST and GST-Arf6 were used as baits in pull-down assays 
from FE65-transfected cells. Fe65 was detected using mouse anti-myc antibody 
(9B11), which recognizes the engineered myc sequence at the C-terminus of FE65. 
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Fig 2.2 Co-immunoprecipitation of Arf6 and FE65. Immunoprecipitations were 
performed from CHO-Kl cells either transfected with FE65 or FE65 + Arf6-myc. 
Arf6-myc was immunoprecipitated by mouse anti-myc antibody 9B11. The 
immunoprecipitated Arf6-myc was detected by a rabbit anti-myc antibody. 
Co-immunoprecipitated FE65 was detected using a rabbit anti-FE65 antibody. (-) and 
(+) refer to the absence or presence of the anti-myc antibody 9B11 in the experiment. 
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2.3.2 Determination of the interacting domain of FE65 with Arf6 
FE65 is a scaffolding protein that consists of three protein-protein interacting 
domains. I n order to determine the domain of FE65 which interacts with Arf6, 
GST-FE65 WW, GST-FE65 PTBl and GST-FE65 PTB2 were co-expressed with 
Arf6-myc in CHO-Kl. GST-FE65 domain proteins were pulled down using 
Glutathione Sepharose 4 Fast Flow resins. The presence of Arf6 was detected by 
9B11, while GST-FE65 domains were detected with an anti-GST antibody. 
Fig 2.3 shows that glutathione sepharose was able to pull down comparable 
amounts of the GST-FE65 domain fusion proteins. The. FE65 domain proteins, 
together with their binding partners, were analysed by Western blotting. It is revealed 
that a significant amount of Arf6 was pulled down with GST-FE65 PTBl, but not 
with GST-FE65 WW, GST-FE65 PTB2 or GST alone. The result suggests that the 
PTBl domain of FE65 is responsible for the interaction between Arf6 and FE65. 
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Lysates Pull downs 
Arf6 
GST-baits 
Fig 2.3 Arf6 interacts with the FE65 PTBl domain in mammalian cells. Myc-Arf6 
was co-transfected with mammalian expression vectors of GST-FE65 WW, 
GST-FE65 P T B l , GST-FE65 PT B2 or GST (Control). The GST-pull down was 
performed as described in section 2.2.10. Arf6-myc was detected using a mouse 
anti-myc antibody (9B11) (Upper panel). 
anti-GST antibody (Lower panel). 
The GST-baits were detected with an 
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2.3.3 Determination if FE65 and Arf6 interact directly 
To order to determine if Arf6 and FE65 interact directly or if their interaction 
requires other factors, a GST-pull down assay was performed between purified Arf6 
and purified GST-FE65 PTBl proteins. When immobilized on glutathione sepharose, 
GST-FE65 PTBl could pull down the bacterial expressed and purified Arf6 (Fig 2.4) 
(See 3.1.1 for purification of bacterial expressed Arf6). However, a similar amount of 
GST could not pull down a significant level of Arf6 protein. The result indicates that 
the FE65 PTBl domain alone is sufficient for interaction with Arf6. 
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Fig 2.4 Arf6 and FE65 interact directly in vitro. (A) Bacterial expressed GST, 
GST-FE65 PTBl and Arf6 were purified to a high purity and resolved in an 
SDS-polyacrylamide gel. (B) Purified bacterial GST and GST-FE65 PTBl were used 
as baits in pull-down assays against purified bacterial Arf6. The existence of Arf6 
was revealed with a commercial anti-Arf6 antibody (upper panel). Lower panel 
shows the the GST and GST-FE65 PTBl baits used in the pull-down assays. 
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Chapter 3 Production of Antisera against Arf6 and 
Immunostaining of FE65-Arf6 
In order to facilitate the study of Arf6 and FE65, an antibody against Arf6 would 
be essential. We have tested several commercially available anti-Arf6 antibodies. 
However, their potencies were not sufficient to detect endogenous Arf6. This will 
limit our further investigations. Thus I have attempted to raise polyclonal antibodies 
against Arf6. Bacterial expressed Arf6 protein was purified and used to immunize 
Sprague-Dawley (SD) rats. The rats were bled and the collected sera were 
characterized by Western blot and immunofluorescence analyses. 
3.1 Materials 
3.1.1 Protein expression and purification 
Isopropyl p-D-thiogalactopyranoside (IPTG) was purchased from Shanghai 
Shenergy Biocolor Bioscience & Technology. Reduced glutathione was purchased 
from Amresco. Kanamycin and chloramphenicol were purchased from USB 
Chemicals and were used at a final concentration of 10 or 35 fig/ml, respectively. 
Solution filtering was facilitated with a vacuum pump filter system (Nalgene) and 
0.025 |im VSWP Membrane Filters (Millipore). Protein concentration was facilitated 
with Amicon Ultra lOK purchased from Millipore. Glutathione Sepharose 4 Fastflow, 
Akta Prime and Superdex-75 were obtained from GE Healthcare. Rosetta 2 (DE3) 
was obtained from Novagen. Bradford reagent was purchased from Sigma. Precision 
protease was a generous gift from Dr. Shannon Au (CUHK). 
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3.1.2 Immunization and harvest of antisera 
Freud's Complete Adjuvant and Freud's Incomplete Adjuvant were purchased 
from Sigma. Adult Sprague-Dawley Rats (SD) were experimented according to 
guidelines of the CUHK Animal Experimentation Ethics Committee. Antibodies 
present in the collect sera were purified with the Melon Gel IgG Spin Purification Kit 
from Thermo Scientific. 
3.1.3 Immunostaining 
Thirteen-millimetre cover glass was purchased from Marienfeld Gmbh. The 
fluorescent microscope used in the experiment was Olympus 1X71 Research Inverted 
Microscope. Fluorescent images were captured with DP30BW Olympus Camera. 
Fluorescence mounting medium was purchased from Dako. Any primary antibodies 
used were as described in the previous sections. Paraformaldehyde powder was 
purchased from Sigma. Alexa Fluo 488 Goat anti-mouse IgG, Alexa Fluo 488 
Donkey anti-rat IgG, Alexa Fluo 594 goat anti-mouse, Alexa Fluo 594 goat 
anti-rabbit and 4',6-diamidino-2-phenyl-indole (DAPI) were purchased from 
Invitrogen. 
3.2 Methods 
3.2.1 Protein expression and purification 
The plasmid pGEX-6p-l Arf6 was transformed into competent Rosetta 2 (DE3) 
by incubating the plasmid DNA with the bacterial cells in an ice-cold calcium 
chloride solution for 30 min, followed with a 42°C heat shock for 90 sec and 1 hour 
recovery in LB at 37°C. The bacteria culture was spread onto an agar plate. A single 
colony of the bacteria was picked and grown in 200 ml LB A at 37°C overnight. The 
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next day, five flasks of 750 ml LBA were each inoculated with 40ml overnight LB 
culture. The bacterial culture was grown at 37°C until optical density of the medium 
at 600 nm reached 0.5. IPTG, with a final concentration of 0.1 mM, was added to the 
medium to induce the expression of GST-Arf6 protein. The culture was incubated at 
37°C for 3 hours. 
The bacterial cells were collected by centrifugation at 5,000 g for 6 min, and 
was resuspended in 50 ml NTEH buffer (500 mM NaCl, 20 mM Tris, 5 mM EDTA, 
pH adjusted to 7.6 with HCl) and lysed by sonication with Branson Sonifier 150 at 
power 4 for 10 sec on ice, three times. The suspension was then centrifuged at 30,000 
g for 1 hour and the supernatant was filtered with 0.2 fim filter. The filtered solution 
was then applied to 5 ml Glutathione Sepharose 4 Fast Flow resin and allowed to 
bind at 4°C with rolling for 2 hours. Washing of the resin was performed with 300 ml 
NTEH buffer. Four hundred micrograms precision protease was then applied and 
allowed to perform the protease cut in NTEL buffer (200 mM NaCl, 20 mM Tris, 5 
mM EDTA, pH adjusted to 7.6 with HCl) at 4°C overnight to release the Arf6 protein. 
The next day, the released protein was collected and concentrated to 2 ml. The 
protein sample was then applied to a packed Superdex-75 column under the Akta 
Prime system. The fractions with a desired protein peak were collected and 
concentrated. The purified proteins were analysed by SDS-PAGE to ensure integrity 
and purity. The final concentrations of protein samples were determined by Bradford 
Assay. 
During the preparation of the GST-Arf6 protein, after the cell lysate binded the 
Glutathione Sepharose 4 Fast Flow at 4°C for 2 hours and subsequent washing with 
300 ml NTEH buffer, 40 ml Elution Buffer (10 mM Tris, 20 mM GSH, 200 mM 
NaCl) was used to elute the bound GST-Arf6 protein. The protein was subsequently 
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concentrated to a desired concentration with Amicon Ultra lOK. Other bacterial 
expressed recombinant GST-tagged proteins underwent similar protocols. 
3.2.2 Bradford assay 
In order to determine protein concentration, 1 \x\, 5 fil and 10 \i\ of prepared 
protein samples were diluted to 500 [i\ with H2O. BSA standards were prepared by 
diluting 0.5 |il，1 3 7 i^l and 10 i^l BSA stock solution (1 mg/ml) to 500 [i\ with 
H2O. The protein samples and BSA standards were then mixed thoroughly with 500 
Bradford reagent and incubated at room temperature for 10 min. A blank solution 
was prepared by mixing 500 \x\ Bradford reagent with 500 \i\ H2O. The absorbance of 
the protein samples and standard solutions at 595 nm was measured. A standard 
curve of OD595 against BSA protein concentration was plotted, and the concentration 
of the protein samples was thus determined from the standard curve. 
3.2.3 Immunization 
In the first immunization of the Sprague-Dawley (SD) rats, each rat was injected 
intraperitoneal with a thorough mixture of 100 |il GST-Arf6 protein (0.5 mg) and 100 
[i\ Freud's complete adjuvant. Four additional immunizations were performed, each 
with a mixture of 100 [i\ protein (0.5 mg) and 100 )il Freud's incomplete adjuvant. 
The mixing of adjuvants with proteins was conducted as follows. First the 
adjuvants were vortexed to make a homogeneous suspension. Two hundred fifty 
microlitres protein (5 mg/ml) and 250 p.! adjuvant suspension were drawn with two 
separate 2.5 ml syringes respectively. The needles of the syringes were then removed 
and then connected through a 2-way luer fitting. The plunger of the syringe 
containing the protein solution was depressed first, forcing its contents into the 
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adjuvant. The two plungers were then pushed alternately for 20 min. After 20 min, 
the plungers would be able to push with little resistance. In order to check the quality 
of the emulsion formed, a drop of the emulsion was placed on the surface of a saline 
solution. If the drop does not disperse, it would be ready for immunization. 
The immunizations of protein-adjuvant emulsion into rats were performed 
fortnightly for five times. Terminal bleeding from the hearts of the anesthetized rats 
was performed two weeks after the final immunization. All animal handling 
procedures were performed according to the guidelines of the CUHK Animal 
Experimentation Ethics Committee. 
The blood samples collected from the rats were allowed to clot at 4°C overnight. 
The sera were separated from the blood clots by centrifugation at 400 g for 10 min 
after gentle disruption with a Pasteur pipette. The blood clots were then washed with 
1 ml PBS, which were then collected and pooled to the sera, respectively. Sodium 
azide (final concentration of 0.05%) was added to prevent bacterial growth. 
3.2.4 Antibody purification 
Antibodies were purified from the sera using the Melon Gel IgG Spin 
Purification Kit. Firstly, the purification column was packed by adding 500 |il 
properly swirled slurry into a Spin Column placed in a microcentrifuge tube. The 
column was centrifuged at 4,500 g for 1 min and the flow through was discarded. 
Three hundred microlitres Purification Buffer was added to wash the column, which 
was then centrifuged at 4,500 g for 10 sec. The flow through was discarded. The 
washing process was repeated again. Then the bottom cap of the Spin Column was 
placed. Then the serum was diluted 10-fold, by adding 450 [i\ Melon Gel Purification 
Buffer to 50 jil antiserum for each purification reaction. The 500 [l\ diluted serum 
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was added to the column, which was then capped and incubated at room temperature 
for 5 min after inverting. The bottom cap and the top cap were removed and the Spin 
Column was placed in a new collection tube, which was then centrifuged at 4,500 g 
for 1 min. The purified antibody was ready for other applications. 
3.2.5 Immunostaining 
C0S7 cells were cultured and transfected, as described in section 2.2.7, in a 
24-well plate placed with 13 mm cover glass. Two days after transfection they were 
immunostained. The cells were firstly washed with PBS at room temperature and 
then fixed with 0.25 ml PBS with 4% paraformaldehyde for 10 min to fix the cells. 
They were then washed with PBS 3 times and permeabilized with 0.25 ml PBS with 
0.1% Triton X-100 for 15 min. The cells were subsequently blocked with the 
blocking solution (0.25 ml PBS with 5% FBS) for 30 min. Primary antibodies were 
diluted in an appropriate dilution (1:500 unless stated otherwise) with the blocking 
solution and then added to the cells and incubate at room temperature for 1 hour. 
After washing with PBS thrice, the cells were incubated with the 
fluorochome-conjugated secondary antibodies (diluted to 1:500 with the blocking 
solution unless stated otherwise) for 1 hour at room temperature. They were then 
washed with PBS once and stained with DAPI for 1 min. After three rounds of 
washing with PBS, the cover glasses were mounted on glass slides with fluorescence 
mounting medium. The slides were allowed to dry overnight before observing under 
an inverted fluorescent microscope. 
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3.3 Results 
3.3.1 Recombinant Arf6 expression and purification 
In order to produce antibodies against Arf6, a high purity of Arf6 protein was 
produced. Firstly, GST-Arf6 protein was expressed in Rosetta 2 (DE3) cells. The 
molecular weight of GST-Arf6 is roughly equal to the sum of the molecular weights 
of GST and Arf6, i.e., 45 kDa (Fig 3.1). Recombinant GST-Arf6 was observed in 
both soluble and insoluble fractions after IPTG induction (Fig 3.1 lane 2 and 4). 
However, the amount of GST-Arf6 that existed in the soluble fraction might be 
sufficient for my purification purpose. Therefore, the soluble fraction was allowed to 
bind on a glutathione sepharose column. 
After two hours of binding, the column was then washed to remove cellular 
impurities. Precision protease was applied to cleave the Arf6 protein from its GST 
tag. The GST tag would retain onto the column while the Arf6 protein was 
subsequently eluted and concentrated (Fig 3.2). It is observed that a small amount of 
GST protein was present in the concentrated Arf6 sample (Fig 3.2 lane 3). The 
residual GST protein was removed by a second binding of the samples with 
glutathione sepharose, which would capture the GST in the sample, and Arf6 
proteins with a high purity was produced (Fig 3.3 lane 1). Its concentration was 
around 0.75 mg/ml before protein concentration. After protein concentration by 
centrifugation filter devices, its concentration was 5 mg/ml as determined by the 
Bradford assay. 
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2 3 4 
Fig 3.1 Expression of recombinant GST-Arf6. GST-Arf6, with molecular weight 
approximately 45 kDa, was expressed in the both soluble and insoluble fractions of 
Rosetta (DE3) E. coli by 0.1 mM IPTG induction at 3 7 � C for 3 hours. However, the 
amount of GST-Arf6 in the soluble fraction would be sufficient for further 
purification. Therefore, the bacterial cell lysate was then allowed to bind to 
glutathione sepharose column. 
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Fig 3.2. Purification of recombinant Arf6. Recombinant GST-Arf6 was expressed as 
described in section 3.3.1 and Fig 3.1. The bacterial lysate was produced by 
sonication of induced bacteria (Lanel). GST-Arf6 in the bacterial lysate was captured 
by Glutathione Sepharose 4 Fast Flow column. The column was washed and the 
bound recombinant protein was released from the GST tag by adding precision 
protease, which recognizes and cleaves an engineered amino acid sequence between 
the GST tag and Arf6. The released proteins were eluted (Lane2 and Lane3). 
Different amounts of bovine serum albumin (BSA) proteins were loaded in the gel as 
a reference to compare the concentration of the purified protein. 
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Fig 3.3 Concentration of recombinant Arf6. The eluted Arf6 collected from Fig 3.2 
was concentrated. The residual GST contaminant observed in the previous 
SDS-polyacrylamide gel was removed by a second incubation of the eluted Arf6 with 
0.5 ml Glutathione Sepharose 4 Fast Flow slurries for 2 hours at 4°C. The purified 
recombinant Arf6 loaded in this gel was in its final form. Different amounts of BSA 
































3.3.2 Titering of antisera 
The purified recombinant Arf6 protein was mixed with adjuvants and 
immunized into two rats biweekly for ten consecutive weeks. The rats were then bled 
and sacrificed. The collected antisera were named AR3 and AR4, respectively. Their 
potencies and specificities were tested with experiments described below. 
To test the potencies of the AR3 and AR4, Western blot analyses were 
performed using cell lysates of CHO-Kl cells overexpressing Arf6-HA. The sera 
were applied at different concentrations: 1:100, 1:1,000 and 1:10,000. Both AR3 and 
AR4 could detect transfected Arf6 at the concentrations 1:100 and 1:1,000. As 
expected, stronger Arf6 bands were observed at the concentration 1:100. However, 
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Fig 3.4 Titering of Arf6 antisera AR3 and AR4. Cell lysates from untransfected (UT) 
or Arf-HA overexpressing CHO-Kl cells were detected with AR3 (A) or AR4 (B) at 








3.3.3 Determination of antisera specificity 
In order to test the specificity of the sera against the antigen, AR3 and AR4 were 
incubated with 6 |ig，13 |xg or 25 |ig of recombinant Arf6 overnight at 4°C in order to 
quench the Arf6-targeting antibodies. The samples were then centrifuged at 20,000 g 
for 15 min at 4°C to remove any aggregates. The supernatant of the pre-incubated 
sera were then applied to immunoblot CHO-Kl cell lysates overexpressing Arf6, in 
comparison to the untreated sera. It was observed that the sharp band recognized by 
the untreated sera, at around 20 kDa. Arf6 bands disappeared or faded considerably 
after the sera were pre-incubated with their respective antigen (Fig 3.5 lane 4, lane 6 
and lane 8). Therefore, both antisera were specific in recognition of Arf6. The other 
bands present in the blots may be due to non-specific binding of proteins, some 
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Fig 3.5 AR3 and AR4 recognize Arf6 specifically. In order to quench the antibody 
activities in the sera specific against Arf6, the sera were pre-incubated with the 
antigen GST-Arf6 overnight at 4°C. The amount of antigen pre-incubated was as 
indicated: 0 |_ig，6 |xg, 12 or 25 p-g. After pre-incubation, the antibodies were spun 
down and the supernatants were used to detect Arf6-HA from untransfected (UT) or 
Arf6-HA transfected CHO-Kl cell lysates at a dilution of 1:100. 
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3.3.4 Detection of endogenous Arf6 
As mentioned earlier, we have failed to detect endogenous Arf6 using 
commercial anti-Arf6 antibodies. To test if our anti-Arf6 antibodies recognize 
endogenous Arf6, the purified AR3 and AR4 were used to detect Arf6 in hamster 
tissues. The following tissues from hamster were tested: brain, heart lung, liver, 
spleen, kidney and testis. Thirty micrograms total proteins from each tissue were 
loaded in gel. Fig 3.6 A shows the Coomassie Blue staining of SDS-polyacrylamide 
gel of the tissue proteins loaded. It confirmed that roughly equal amounts of total 
proteins from different tissues were loaded in each lane. Purified AR3 and AR4 were 
used to detect endogenous Arf6 in the tissues (Fig 3.6 B and C). It is observed that 
bands with a molecular weight similar to the overexpressed Arf6-HA were observed 
in various tissues including the brain, lung, liver, kidney, spleen and testis. However, 
Arf6 was not detected in the heart. Our results are similar to the reported tissue 
distribution of Arf6 (Tsuchiya et al., 1991). It is also noticed that stronger Arf6 bands 
were detected by purified AR3 which 
recognizing endogenous Arf6 than AR4. 
suggests that AR3 is more potent in 
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Fig 3.6 AR3 and AR4 detected endogenous Arf6 in hamster tissues. (A) An 
SDS-PAGE of the hamster tissue lysates to show the amounts of protein used for 
Western blot analyses. Each lane was loaded with approximately 30 |ig of total 
protein. The lane Arf6-HA indicates the cell lysate was from Arf6-HA transfected 
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CHO-Kl, which serves as a reference for the molecular weight of the Arf6 protein. 
The protein amount in each lane was similar, except for cell lysate of Arf6-HA 
transfected CHO-Kl. (B) AR3 was able to detect Arf6 in the hamster brain, lung, 
liver, kidney, spleen, and testis and, to a lower level, the hamster heart. (C) AR4 was 
able to detect Arf6 in the hamster liver and kidney and, to a lower level, the hamster 
brain, heart, lung, spleen and testis. 
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3.3.5 Immunostaining 
To test if AR3 and AR4 are specific in the recognition of Arf6 in mammalian 
cells, immunostaining experiments were conducted as follows. Arf6-HA was 
overexpressed in C0S7 cells and immunostained with mouse anti-HA antibody 
(12CA5) and AR3/AR4, as shown in Fig 3.7. Goat anti-rat 488 and donkey 
anti-mouse 594 fluorochrome-conjugated secondary antibodies were used to 
recognize the primary antibodies and produce the fluorescent signals. Cell nuclei was 
stained by DAPI. The result shows that AR3 and AR4 could give identical 
immunostaining patterns to that of 12CA5. Thus, AR3 and AR4 could specifically 
recognize Arf6 in mammalian cells. 
Since the Arf6 antibodies were able to detect Arf6 specifically, experiments 
were conducted to detect if FE65 and Arf6 colocalize in mammalian cells. Arf6-HA 
and FE65 were co-expressed in C0S7 cells. Subsequently the cells were 
immunostained with AR3 and a rabbit anti-FE65 antibody. Goat anti-rat 488 and 
donkey anti-rabbit 594 secondary antibodies, which were conjugated to 
fluorochromes as indicated, were used to recognize the primary antibodies. The cell 
nuclei were detected with DAPI. The results were shown in Fig 3.8. 
Cells transfected with only FE65 showed a broadly distributed localization. It 
was observed mainly at the nucleus and cytoplasm. This localization matches reports 
by other groups (Kimberly et al., 2001; Minopoli et al., 2001; Nakaya et al., 2008; 
Sabo et al., 2003; Yang et al., 2006). Cells transfected with only Arf6 showed a 
mainly vesicular localization, with a partial plasma membrane distribution, as 
described by other researchers (Gaschet and Hsu, 1999; Macia et al., 2004). 
In FE65 and Arf6 co-transfected cells, the two proteins were found colocalized 








Fig 3.7 AR3 and AR4 were specific for Arf6 in immunostaining experiments on 
mammalian cells. Immunostaining of Arf6-HA transfected C0S7 cells with 
AR3/AR4 and 12CA5, a mouse anti-HA antibody. Goat anti-rat 488 was used to 
recognize AR3 and AR4. 12CA5 was detected by goat anti-mouse 594. Cell nuclei 
were labeled with 4' ,6-diamidino-2-phenyl-indole (DAPI). Overlay of the images 
was in yellow, showing that the immunostaining image of Arf6 and HA totally 
overlap. This indicates that AR3 and AR4 could detect Arf6 specifically in 
mammalian cells. All images are of the same scale and the scale bar equals 10 [im. 
(Please note that the images were overexposed in order to visualize the plasma 





FE65 + Arf6 
Fig 3.8 FE65 colocalizes with Arf6 at perinuclear vesicles. C0S7 cells were 
transfected with either Arf6, FE65 or FE65 + Arf6. FE65 was detected with a rabbit 
anti-FE65 antibody, Arf6 was detected with AR3. Fluorochrome-conjugated 
antibodies, donkey anti-rat 488 and goat anti-rabbit 594, were used to recognize the 
primary antibodies. Fluorescent imaging shows that FE65 and Arf6 partially 
colocalize at the perinuclear vesicles. Cell nuclei were stained with DAPI. Scale bar 
represents 10 |im. (However, due to the limit of the printing equipment, the 
resolution appears in the figure may not be clear enough. Electronic versions of 
better resolution will be provided upon request to demonstration the colocalization.) 
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Chapter 4 Discussion 
FE65 is an adaptor protein reported to participate in a wide variety of cellular 
events including gene transcriptional regulation and cell migration. Importantly, 
FE65 may also play a role in AD pathogenesis. To date, its precise roles in cells are 
still not fully understood. This project aims at identifying novel interacting partners 
of FE65, which would allow us to have a better understanding of its significances. 
By using various interaction assays and immunostaining analyses, here I have 
demonstrated that Arf6 interacts with FE65 PTBl domain and the two proteins 
colocalize in transfected cells. Arf6 is a member of the Arf protein family. It is a 
Ras-related small GTP-binding protein involved in the regulation of vesicular 
transport through the endocytic and secretory pathways (D'Souza-Schorey and 
Chavrier，2006; D'Souza-Schorey et al., 1998; Donaldson, 2003; Hosaka et al., 1996; 
Maranda et al., 2001; Montagnac et al•，2009; Palacios et al., 2001; Poupart et al., 
2007; Radhakrishna and Donaldson, 1997; Tanabe et al., 2005). Arf6 also plays a 
significant role in the reorganization of actin cytoskeleton and membrane structures, 
thus functioning in cell motility, cell adhesion and the formation of invasive 
podosomes (Bose et al., 2001; Donaldson, 2003; Hiroyama and Exton, 2005; Luton 
et al., 2004; Randazzo et al., 2007; Santy and Casanova, 2001; Svensson et al., 2008; 
Turner and Brown, 2001; Valderrama and Ridley, 2008). As demonstrated in section 
3.3.4, Arf6 is expressed in many different tissues including the brain, lung, liver and 
kidney. (Dressier et al., 1996; Hosaka et al., 1996; Tsuchiya et al., 1991) 
I have demonstrated that FE65 interacts directly with Arf6 through its PTBl 
domain. In fact, FE65 is not the first PTB-containing protein that interacts with Arf6. 
It is reported that the inactivated form of Arf6 interacts with GULP, a 
68 
PTB-containing protein involved in endocytosis and in engulfment of apoptotic cells 
(Liu and Hengartner, 1998; Ma et al., 2007; Martins-Silva et al., 2006). In addition, 
Arf3, a close paralogue (>60% identical) of Arf6, is shown to interact with a family 
of PTB-containing proteins Xlla/p/y through their PTB domains (Hill et al., 2003). 
The PTB domains are renounced adaptor or scaffolding modules important in 
organizing signal complexes (Uhlik et a l , 2005). Therefore, it is possible that Arf 
proteins associate with PTB-containing proteins to carry out their cellular functions. 
The above PTB -containing proteins have been shown to have prominent neuronal 
functions (Guenette et al., 2006; Ho et al., 2006; Martins-Silva et al., 2006; 
Santiard-Baron et al., 2005; Shrivastava-Ranjan et al., 2008). Thus the interaction 
between Arf6 and the PTBl domain of FE65 may also have important implications in 
neuronal functions. 
An important aspect of FE65 is its role in AD pathogenesis. FE65 has a high 
affinity towards the intracellular domain of APP (Borg et al., 1996; Fiore et al., 1995; 
Lau et al., 2000; Muresan and Muresan, 2005). It is reported to influence APP 
processing in cellular and animal models (Guenette et al., 2006; Sabo et al., 1999; 
Santiard-Baron et a l , 2005; Wang et al., 2004). It is interesting to note that the 
proteolytic cleavage of APP mainly occurs in the secretory and endocytic vesicles, 
while Ar f6 plays a pivotal role in different modes of endocytosis, recycling of 
membrane proteins and endosomal dynamics in neurons (Claing, 2004; 
D'Souza-Schorey et al., 1995; Hernandez-Deviez et al., 2007; Nixon, 2004; Poupart 
et al., 2007). Additionally, Arf3, a paralogue of Arf6 that is responsible for 
Golgi-to-plasma membrane transport, is reported to transport APP to cell membrane 
(Hill et a l , 2003; Shrivastava-Ranjan et al., 2008). Furthermore, an effector of Arf6, 
Golgi associated, gamma adaptin ear containing, ARF binding protein 3 (GGA3), is 
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reported to mediate APP processing through regulation of BACE trafficking and 
activity (Tesco et al., 2007). Thus it raises the possibility that the FE65-Arf6 
interaction may be involved in the internalization, recycling and processing of APP. 
It is possible that Arf6 recruits APP into endosome for proteolytic cleavage through 
the adaptor protein FE65. However, further experiments would be required to 
examine the effects of Arf6 on APP recycling and processing. 
Another function of FE65 in cells and animals is the regulation of cell 
movement and cell migration (Guenette et al., 2006; Sabo et al., 2001). FE65 
interacts with APP and Mena to regulate cell motility (Muller et al., 2008; Sabo et a l , 
2001). They colocalize at neuronal growth cones and synapses, where actin and 
membrane remodeling occur frequently (Sabo et al., 2003). Similarly, Arf6 is also 
involved in cell adhesion, cell motility and cell invasion, by endocytosis of surface 
proteins and regulation of actin and membrane remodeling (Al-Awar et al., 2000 
Donaldson, 2003; Dunphy et al., 2006; Hoover et al., 2005; Luton et al., 2004 
Morishige et al., 2008; Myers and Casanova, 2008; Powelka et al., 2004 
Radhakrishna et a l , 1999; Sabe, 2003; Tague et al., 2004; Turner and Brown, 2001 
Valderrama and Ridley, 2008). As both FE65 and Arf6 are involved in cell motility 
and they interact with each other, it is possible that they contribute to this aspect via a 
common pathway. 
During the course of this project, polyclonal antibodies against Arf6 were raised. 
The anti-Arf6 antibodies have been used successfully in immunoblotting and 
immunostaining experiments. Results from immunostaining analyses by these 
antibodies indicate that Arf6 and FE65 colocalize at the perinuclear vesicles. It is 
known that the subcellular localization and functions of Arf6 are dependent on its 
GDP/GTP cycles. The activated GTP-bound form of Arf6 is localized at the plasma 
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membrane, while its GDP-bound form is localized at recycling vesicles (Peters et al., 
1995). The interaction between Arf6 and its effectors are also regulated by its 
activation status (Paleotti et a l , 2005; Takatsu et al., 2002). As Arf6 interacts with 
FE65, it would be interesting to know if FE65 influences the GTP/GDP cycle of 
Arf6. 
Through the immunostaining analyses, the polyclonal antibodies generated in 
the project have facilitated our investigation of the probable sites of action of the 
FE65-Arf6 complex. In fact, purified polyclonal antibodies are particularly efficient 
in immunostaining experiments due to their specificity for a broad range of epitopes 
present on the antigen (Caponi and Migliorini, 1999). Even heavily fixed samples 
may still retain a large number of epitopes detectable by polyclonal antibodies. 
Moreover, the antibodies produced can be further utilized in other studies. For 
example, since the purified antibodies are able to detect endogenous Arf6 proteins 
from various hamster tissues, it would be interesting to perform immunoprecipitation 
of the endogenous Arf6-FE65 complex from hamster organs. This would provide 
further evidence that the interaction between the proteins occurs in vivo. The 
antibodies raised in the experiment can also be used for histochemical staining 
analysis of tissues. For example, by observing and comparing the localization of Arf6 
in areas of the brain with that of FE65, we can obtain more information regarding 
where the Arf6-FE65 complex functions, and to speculate the significance of their 
interaction in the areas. The same technique is also applicable to tissues other than 
the brain. This might help disclose more physiological significances of the protein. 
The anti-Arf6 antibodies may also be useful in investigation of AD pathogenesis. 
One of the AD pathological signs is deposition of Ap production to form amyloid 
plaques in the brains (Iwata et al., 2005). Immunostaining of Arf6 and APP with cells 
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overexpressing these two proteins would also be valuable in determining if Arf6 is 
involved in the recycling of APR If these two proteins colocalize at endosomal 
structures or plasma membrane, it may suggest that Arf6 regulates APP 
internalization. Histochemical staining of post mortem tissues from AD patients with 
antibodies against Arf6, APP and FE65 to determine if these proteins colocalize in 
the affected regions in the AD brains. If Arf6 is abundantly found at the endosomes 
where APP and FE65 colocalize, this may indicate that APP recycling and cleavage 
are mediated by both FE65 and Arf6. Again, further investigation is required. 
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Chapter 5 Future Perspectives 
In this report, I have demonstrated that Arf6 interacts with FE65 through its 
PTB domain. However, the whole picture and significances of the interactions are far 
from complete. As I have generated anti-Arf6 antibodies that can detect endogenous 
Arf6, this can facilitate our future studies. In order to validate if FE65 and Arf6 
interact in vivo, endogenous immunoprecipitation can be carried out. By 
immunoprecipitating Arf6 from endogenous tissues with the raised antisera and 
subsequent immunoblotting with FE65 antibodies, the presence or level of 
endogenous FE65-Arf6 complex can be detected. This would verify that the 
interaction is physiological and not experimental artifact that occurs only under 
overexpression of the proteins. 
From the amino acid sequence, FE65 does not contain protein modules 
necessary for enhancing guanine nucleotide exchange (GEF) or GTPase-activation 
(Bressler et al., 1996; McLoughlin and Miller, 2008). However, being an adaptor 
protein with three protein-protein interacting modules, FE65 may regulate the 
activation state of Arf6 through its interacting partners. Thus it is interesting to 
investigate if the GTP/GDP state of Arf6 is changed when FE65 is co-expressed. The 
GTP/GDP state of Arf6 can be investigated by GGA3- or MT2- pull down assays. 
GGA3 and MT2 are proteins that can specifically bind GTP-bound Arf6 but not its 
GDP-bound form (Dell'Angelica et al., 2000; Schweitzer and D丨Souza-Schorey， 
2002). Therefore, by investigating if there are shifts in the amount of GTP-bound 
Arf6 proteins when FE65 is co-expressed, it is possible to see if the activation state 
of Arf6 is affected. 
In addition, more subtle characteristics of the interaction can be assayed. For 
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example, a number of studies suggest that the interactions between Arf6 and its 
effectors are regulated by its GDP/GTP cycles (Paleotti et al., 2005; Takatsu et al.’ 
2002). Thus we can investigate if there are differences in affinity between activated/ 
inactivated Arf6 and FE65. This could help understanding the significances of the 
interaction, as different forms of Arf6 are different in subcellular localization and are 
associated with different partners and effectors. This can be done be conducting 
experiments between FE65 and mutants of Arf6. Arf6 T27N is considered as a 
nucleotide binding-deficient mutant, while Arf6 Q67L is a mutant deprived of its 
hydrolytic capabilities and is thus mostly GTP-bound (Cavenagh et al., 1996; 
D'Souza-Schorey et al., 1995; Peters et al., 1995). By assaying the interactions 
between FE65 and the mutant and wildtype forms of Arf6, it is possible to 
understand if the activation state of Arf6 regulates its interaction with FE65. 
This novel interaction between FE65 and Arf6 uncovers many possible aspects 
of investigation that might help to add further information and understand the vast 
number of cellular processes that the adaptor protein FE65 and the small 
GTP-binding protein Arf6 involve in. 
Since FE65 is an adaptor protein that is able to bind more than one protein 
simultaneously, it is possible that FE65, Arf6 and other proteins form tertiary or 
higher complexes (McLoughlin and Miller, 2008; Russo et al., 1998). The antisera 
raised would also be useful in determining if the FE65-Arf6 complex further 
interacts with other proteins simultaneously. This can be done by overexpressing and 
immunoprecipitating Arf6, and immunoblotting for other binding partners of FE65, 
such as APP and Mena, when FE65 is or is not overexpressed. If these proteins are 
detected only when FE65 is overexpressed, it suggests that proteins complexes are 
formed and FE65 acts as a bridge between Arf6 and other proteins. This would help 
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to understand the cellular functions and significances of the FE65-Arf6 interaction. 
The functional consequences of the FE65-Arf6 are also an important target of 
further investigation. There are many reports showing that FE65 influences APP 
processing (Guenette et al., 2006; Sabo et al.，1999; Santiard-Baron et al., 2005; 
Wang et al., 2004). In addition, Arf3, an paralogue of Arf6, is also reported to 
regulate APP trafficking (Hill et al., 2003; Shrivastava-Ranjan et al., 2008). 
Furthermore, GGA3, an effector of Arf6, is shown to involve in APP processing 
(Tesco et al., 2007). Therefore, it is possible that FE65 and Arf6 cooperate to mediate 
APP recycling or cleavage. This can be verified by overexpression of the three 
proteins in mammalian cell, with subsequent detection of the cleavage products of 
APP. If a higher level of APP C-terminal fragment (CTF) or Ap is detected, this may 
imply a role of Arf6 in APP processing. 
Furthermore, Arf6 is a well-established regulator of cytoskeleton, cell adhesion 
and invasion (Bose et al., 2001; Donaldson, 2003; Hiroyama and Exton, 2005; Luton 
et a l , 2004; Randazzo et al., 2007; Santy and Casanova, 2001; Svensson et al., 2008; 
Turner and Brown, 2001; Valderrama and Ridley, 2008). FE65 is also reported to 
regulate cell motility and cell migration, e.g. through its interactors APP and Mena 
(Guenette et al., 2006; Sabo et al., 2001). Therefore, it is possible that the FE65-Arf6 
complex functions in mediating cell migration. There are several well-established 
standard assays for this type of experiments. One of them is the wound healing assay, 
which investigates the time required (in terms of hours) for a monolayer of cultured 
epithelial cells to close a scratch wound by cell migration (Liang et al., 2007). If 
co-expression of FE65 and Arf6 can accelerate the closure of the wound, it suggests 
that they cooperate to enhance cell migration. 
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